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Abstract  
 
 
Machado-Joseph disease (MJD), also known as Spinocerebellar Ataxia 3 (SCA3), is the most 
common autosomal dominant ataxia worldwide, and is caused by a CAG repeat expansion within the 
coding region of the ATXN3 gene. The clinical variability of the disease phenotype as well as the age 
of onset depend on the length of the expanded repeat. The anticipation phenomenon is most 
frequently associated with repeat expansions in paternal transmission. MJD patients with a repeat 
expansion above 44 CAGs in the ATXN3 gene present cytoplasmic and/or intranuclear ataxin-3 
aggregates and neuronal cell loss in specific areas of the brain. However, some questions remains 
unanswered in this disease: why only some subpopulations of neurons are affected, although ataxin-
3 is everywhere; what underlies this selective neuronal vulnerability; are these neurons dysfunctional 
or dying? 
In an attempt to address these issues, we took advantage of studying a cDNA transgenic 
mouse model (CMVMJD) expressing the mutant human ataxin-3 under the regulation of the CMV 
promoter (pCMV), previously generated in our lab. This transgenic mouse model shows an important 
overlap with genetic and clinical features of MJD, namely genetic instability of the expanded CAG 
repeat and a motor impairment phenotype. 
In this work, we performed an extensive pathological analysis of MJD mouse brains, that 
revealed a significant atrophy in the thalamus and in the dentate neurons. Increased GFAP 
immunostaining with reactive astrocytes was observed in the vestibular nuclei and substantia nigra 
of transgenic mice. Regarding cell death, we have searched for evidence of different cell death types 
(apoptosis and necrosis) by TUNEL assay, caspase-3 analysis and Fluoro-Jade B staining. We did not 
find any differences between wild-type and MJD transgenic mice, suggesting that probably the 
affected neurons are not dying, at least by apoptosis or necrosis, instead, they might just be 
dysfunctional. We also analysed of the somatic mosaicism in neuronal and non-neuronal tissues 
through aging revealed a significant increase in the mosaicism index of specific brain regions such 
as the pons, substantia nigra, cerebellar cortex, hipocampus, striatum, deep cerebellar nuclei and 
hypothalamus with age. However, there was no correlation between the extent of the mosaicism and 
the pathological involvement of a given region. 
 The results allow us to conclude that the pCMVMJD94 mouse is a good model to 
study the pathogenic mechanisms of MJD, mimicking an early stage of the disease. 
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Resumo 
 
 A doença de Machado-Joseph, também conhecida por Ataxia Espinocerebelosa tipo 
3 (SCA3), é a ataxia autossómica dominante mais comum em todo o mundo, causada por uma 
repetição de CAGs na região codificante do gene ATXN3. A variabilidade no fenótipo da doença 
assim como a idade de surgimento dos sintomas depende no tamanho da repetição expandida. O 
fenómeno de antecipação está mais frequentemente associado a transmissões paternas. Pacientes 
com DMJ com expansões acima de 44 CAGs revelam agregados citoplasmáticos e /ou nucleares e 
perda neuronal em áreas do cérebro específicas. Algumas questões chave permanecem por 
esclarecer. Por exemplo, nesta doença apenas algumas subpopulações de neurónios são afectadas, 
embora a ataxina-3 seja expressa em todas as áreas. O que está por detrás desta vulnerabilidade 
neuronal selectiva? Estarão estes neurónios a morrer ou estarão disfuncionais? Numa tentativa de 
responder a estas perguntas, utilizámos um modelo em ratinho que expressa o cDNA da ataxina-3 
humana mutada, sob a regulação do promotor CMV (pCMV), previamente gerado no nosso 
laboratório. Neste trabalho, fizemos uma extensa análise patológica de cérebros de ratinho DMJ que 
revelaram uma atrofia relevante no tálamo e núcleos denteados. Também se observou um aumento 
da proteína GFAP, revelando um aumento da reactividade dos astrócitos, nos núcleos vestibular e 
substantia nigra dos ratinhos transgénicos. Também fizemos um rastreio de diferentes tipos de 
morte celular (apoptose e necrose) por TUNEL, análise da activação da caspase-3 
(imunohistoquímica e western-blot) e coloração com Fluoro-Jade B. Não encontrámos diferenças 
significativas entre ratinhos do tipo selvagem e transgénicos, sugerindo que provavelmente estes 
neurónios não estarão a morrer, pelo menos por apoptose ou necrose, estando possivelmente 
disfuncionais. Para além disso, a repetição de CAG expandida, variou em mais de 50% das 
transmissões nos ratinhos transgénicos, com expansões típica transmitidas em meioses paternas e 
contracções em maternas. A análise do mosaicismo somático em tecidos neuronais e periféricos, 
durante o envelhecimento, revelou um aumento no índex de mosaicismo em regiões específicas do 
cérebro e mostrou ser dependente da idade. Este ratinho transgénico apresenta características 
genéticas e clínicas importantes que se sobrepõem às da DMJ, nomeadamente instabilidade 
intergeracional da expansão de CAGs, características patológicas da doença (astrogliose e neurónios 
atrofiados, nas regiões relevantes) e um fenótipo de descoordenação motora.  
Estes resultados permitiram-nos concluir que o ratinho pCMVMJD94 é um bom modelo 
para estudar os mecanismos patogénicos da DMJ, mimetizando estadios precoces da doença. 
 xii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xiii 
 
Contents 
 
Dedication .......................................................................................................................... iii 
Agradecimentos/Acknowledgments .................................................................................v 
Abstract .............................................................................................................................. ix 
Resumo .............................................................................................................................. xi 
Abbreviations ................................................................................................................... xv 
Chapter 1. General Introduction ....................................................................................... 3 
1.1 Polyglutamine disorders: an overview......................................................................... 3 
1.2 Instability of the CAG repeat ........................................................................................ 5 
1.3 Polyglutamine pathogenic mechanisms ...................................................................... 7 
1.3.1 Misfolded proteins and aggregation ..................................................................... 7 
1.3.2 Transcriptional deregulation ................................................................................. 8 
1.3.3 Mitochondrial impairment .................................................................................... 9 
1.4 Neuropathology and neuron-specific toxicity in PolyQ diseases .............................. 10 
1.5 Mechanisms of cell death .......................................................................................... 12 
1.6 Machado-Joseph disease ........................................................................................... 16 
1.6.1 Clinical definition ................................................................................................. 16 
1.6.2 Pathology ............................................................................................................ 17 
1.6.3 Genetics ............................................................................................................... 18 
1.6.4 ATXN3 gene product ........................................................................................... 19 
1.7 Different mouse models for the same disease .......................................................... 20 
Chapter 2. Objectives ...................................................................................................... 27 
Chapter 3. Brain pathology in MJD transgenic animals ................................................. 31 
3.1 Background ................................................................................................................ 31 
3.2 Materials and methods .............................................................................................. 32 
3.3 Results and discussion ............................................................................................... 33 
3.4 Conclusion .................................................................................................................. 38 
Chapter 4. Mechanisms of cell death ............................................................................. 41 
4.1 Background ................................................................................................................ 41 
4.2 Materials and methods .............................................................................................. 42 
4.3 Results and discussion ............................................................................................... 45 
 xiv 
 
4.4 Conclusion .................................................................................................................. 52 
 
Chapter 5. CAG repeat instability ................................................................................... 55 
5.1 Background ................................................................................................................ 55 
5.2 Materials and methods .............................................................................................. 57 
5.3 Results and discussion ............................................................................................... 59 
5.4 Conclusion .................................................................................................................. 64 
Chapter 6. General discussion ........................................................................................ 67 
Chapter 7. Main conclusions ........................................................................................... 73 
Chapter 8. Future perspectives ....................................................................................... 77 
Chapter 9. References ..................................................................................................... 81 
 xv 
 
List of Abbreviations 
 
μL –  Microliter 
μm –  Micrometer 
AD – Alzheimer's Disease 
AH – Anterior Horn 
ALS – Amyotrophic Lateral Sclerosis 
AR – Androgen receptor 
AT3 – Ataxin-3 protein 
AT3Q(n) – Ataxin-3 protein containing 
n glutamine residues 
ATXN3 – Ataxin-3 gene 
ATP – Adenosine triphosphate 
AIF – Apoptosis Inducing Factor 
Apaf-1 – Apoptotic peptidase 
activating factor 
AMPA – Agonist of AMPA receptor 
a.a. –Aminoacid 
bp – Base pairs 
C. elegans – Caenorhabditis elegans 
C/P – Caudate/Putamen 
CAG – Trinucleotide codon for 
glutamine 
CBP – CREB binding protein 
 
 
 
cDNA – complementary DNA 
cys – Cysteine 
cyt c – Cytochrome c 
CREB – Cyclic AMP-response Element 
Binding protein 
CNS – Central Nervous System 
CMVp – Cytomegalovirus promoter 
DN – Dentate Nucleus 
DNA – Deoxyribonucleic acid 
DRPLA – Dentatorubral-Pallidoluysian 
Atrophy 
DAB – 3, 34-biiaminobenzidine 
DM – Myotonic Dystrophy 
ECL- Enhanced GChemiLuminescenc 
ER – Endoplasmic reticulum  
E.coli – Escherichia coli 
FADD – Cytosolic adaptors proteins 
GABA – Gamma-Amino Butyric Acid 
GFAP – Glial Fribillary Acidic Protein 
HD – Huntington's Disease 
HDAC – Histone Deacetylase  
Hdj-1 – 40-kDa heat-shock protein 
 xvi 
 
Hdj2 – Constitutive form of 40-kDa 
heat-shock protein 
H&E – Hematoxylin&Eosin 
Hprt – Hypoxanthine Phosphoribosyl 
Transferase 
Hsp – Heat shock protein  
HAT – Histone Acetylase 
Htt – Huntingtin Protein 
H3 – Histone 3 
H4 – Histone 4 
IHC – Immunohistochemistry 
ICE – Interleukin-1b processing 
enzyme 
kDa – KiloDalton(s) 
kb – kilobase 
Lat – Dentate nucleus  
LV – Lentivirus 
LANP – Cerebellar leucine rich acidic 
nuclear protein 
MJD – Machado-Joseph Disease 
mL – Milliliter 
mM – Milimolar 
MMR – Mismatch Repair 
MSH – Mismatch repair gene 
MutSb – MSH2/MSH3 comlex 
mRNA – Messenger RNA 
mtDNA – mitochondrial DNA 
MT – Mitochondria 
MI – Mosaicism Index 
MOMP – Mitochondrial Outer 
Membrane Permeabilization 
n – Number of samples in the study 
NEDD8 – Developmental down-
regulated gene 8 
NMDA – N-methyl-D-aspartic acid 
NAIP – Neuronal Apoptosis Inhibitory 
Protein 
ng – Nanogram 
NI – Neuronal Inclusion 
NLS – Nuclear Localization Signal 
NES – Nuclear Export Signal 
Nm – Namometer 
OH8dG – 8 hydroxydeoxyguanosine 
pCAF – Protein-associated factor 
PCR – Polymerase Chain Reaction 
PFA – Paraformaldehyde 
PD – Parkinson's Disease 
Pn – Pontine Nucleus 
PCD – Programmed Cell Death 
polyQ – Polyglutamine 
 xvii 
 
Q(n) –  stretch of n glutamine 
residues 
Q – Glutamine 
RNA – Ribonucleic acid 
RNAPolII – RNA polymerase II 
ROS – Reactive Oxygen Species 
SCA – Spinocerebellar Ataxia 
SMBA – Spinal and Bulbar Muscular 
Atrophy 
SMA – Spinal Muscular Atrophy 
SAHA – Suberoylanilide Hydroxamic 
Acid 
SH3L3 – SH3 – containing Grb2-like 
protein 
SOD – Superoxide dismutase 
SN – Substantia Nigra 
SP1 – Specificity Protein 1 
SRC1 – Steroid Receptor Coactivator1 
TAFII130 – TBP-associated factor 
TBP – TATA box binding protein 
t-test – Student’s t test 
TH – Tyrosine Hydroxilase 
Th – Thalamus 
TUNEL – Terminal deoxynucleotidyl 
transferase dUTP nick end labeling 
TC-NER – Nucleotide excision repair 
UIM – Ubiquitin-interacting motifs 
UPS – Ubiquitin-proteasome system 
Ve – Vestibular nuclei 
VMAT2 – VVesicular monoamine 
transporter 2 
VCP – Valosin-containing protein 
Wt – Wild-type 
YAC – Yeast Artificial Chromosome 
 
xviii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1. General Introduction 
 
2 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Chapter 1. General Introduction 
3 
Chapter 1. General Introduction 
 
 
1.1 Polyglutamine disorders: an overview 
 
 Expansions of repeating units of DNA, especially CAG triplet repeat expansions, are 
known to underlie several neurodegenerative disorders [6], including Machado-Joseph disease 
(MJD), or spinocerebellar ataxia 3 (SCA3) [4, 7], Huntington disease (HD) [8], spinal and bulbar 
muscular atrophy (SBMA)[9], dentatorubropallidoluysian atrophy (DRPLA) [10-11], and other 
spinocerebellar ataxias, such as SCA 1, 2, 6, 7, and 17. The clinical manifestations of each disease 
result from brain pathology involving a specific subset of neurons that is, for the most part, particular 
to each disease. A common feature among all these disorders is a progressive neuronal 
dysfunction/death beginning at mid-life [4].  
 The progressive neurodegeneration in adulthood and some common symptoms in these 
apparently unrelated disorders have suggested a shared mechanism for their pathogenesis. The 
major pathogenic mechanism of these diseases is believed to arise from a genetic gain of function 
related to abnormal conformation of the elongated polyQ tracts. The CAG expansion leads to an 
abnormally long polyglutamine (polyQ) tract within all the proteins involved in the mentioned 
diseases. Besides this polyQ tract, the proteins share no homology and no functional similarity, 
which suggests that the polyQ stretch itself confers toxic properties to these proteins through a “toxic 
gain of function” [5]. In agreement with this hypothesis the expression of a simple polyQ tract, in the 
absence of any additional protein context has been shown to be toxic, as shown in cell culture, 
mouse, Drosophila and C. elegans [6-10]. This toxic effect of the polyQ tract was further reinforced 
by a study describing the effect of the insertion of a CAG tract in the hypoxanthine-guanine 
phosphoribosyltransferase (HPRT) gene, encoding a metabolic enzyme in mice. These mice 
developed a progressive late-onset neurological phenotype, including ataxia, seizures and premature 
death [12].  
Interestingly, and despite the ubiquitous expression pattern of polyQ mutated proteins, only 
some subsets of neurons are affected in each polyQ disorder (Table1), indicating that there are other 
factors influencing the pathogenesis [4, 21]. Apart from the polyQ tract, the disease associated 
proteins are unrelated to each other, sharing no homology [3, 22-23]. All these proteins are widely 
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expressed in the Central Nervous System (CNS) as well as in peripheral tissues, however each polyQ 
protein originates a different neurodegeneration profile [4]. 
Another interesting fact is the overlap of phenotypes of these disorders when the expansions 
are large: for example, juvenile-onset Huntington patients develop dystonia and seizures in addition 
to the classical phenotype of chorea, dementia, lack of coordination and unsteady gait seen in adult 
patients.  
The CAG repeat tracts are normally highly polymorphic and above a certain threshold length 
the symptoms of the diseases are manifested (Table 1) [1, 4-5]. The disease threshold length (and 
the dominant toxic property) is around 35 to 40 glutamine repetitions. Above the pathogenic 
threshold the CAG tracts are unstable across generations, and it may expand or contract depending 
on the gender of the transmitter. While maternal meioses tend to lead to contractions, paternal 
transmissions tend to lead to expansions. This intergenerational instability leads to a phenomenon 
called “anticipation”, where the disease symptoms appear earlier and are more severe [24-25]. At a 
molecular level, all polyQ diseases display proteinaceous aggregates in neurons, usually termed 
neuronal inclusions (NIs), mainly located in the nucleus [11]. These inclusions are a common 
hallmark of all these diseases and it is still controversial if they are pathogenic or not. 
 
Table 1. Molecular and pathogenic features of polyglutamine diseases. Adapted from [1] [3] [4] 
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1.2. Instability of the CAG repeat  
 
Expanded repeat mutations do not behave strictly according to rules of Mendelian 
inheritance. They are unstable mutations that change in size along successive generations. In 
contrast, normal-sized repeats are usually transmitted stably [26][12]. This instability of the mutant 
alleles might explain some characteristics of these diseases such as variable phenotype [27], 
anticipation and parental-origin effects. The mechanisms that underlie this instability are not very 
well known, but several factors are known to influence it: (i) type of repeated sequence, (ii) gender of 
the transmitting parent [28], (iii) the original length of the repetition tract [29], and (iv) the 
presence/absence of interruptions in the repetitive sequence [24, 30-31]. In this type of disorders, 
severe juvenile-onset cases are usually paternally transmitted, due to the greater repeat instability 
with paternal transmission [32, 33]. For example, analysis of the repeat length in sperm from HD 
patients suggests that this tendency for transmitting expanded repeats is due to repeat instability 
during spermatogenesis [34]. Also, in MJD families the sex of the transmitting parent has a 
significant effect on intergenerational instability, male meioses being associated with larger 
variations, both contractions and expansions, of the repeat size [24, 30-31, 35].   
 
 However, repeat instability is not confined to the germline, occurring also in 
characteristic patterns in many somatic tissues of affected individuals [36]. The ongoing repeat 
instability in critical somatic tissues likely accelerates disease progression. Somatic mosaicism of the 
repeat sizes in triplet repeat disorders shows that different cells of the same individual carry different 
repeat sizes. This phenomenon has never been described for the normal allele, but it has been 
associated to the expanded allele for several polyQ disorders such as MJD [31] and SCA1 [37] as 
well as HD [38], DRPLA [39] and SMBA [40].  
Tissue-specific CAG instability and severity of neuropathological features were proposed to 
be directly correlated in HD [38] but this was not confirmed for other diseases with CAG repeat 
expansions [31, 37, 39-40].  
 
 The existence of a similar threshold size for all trinucleotide repeat diseases may 
suggest a common mechanism for expansion. Slipped-strand mispairing during replication [41-42] 
has been proposed as a mechanism of mutation that could account for several features of the 
trinucleotide expansion. During replication of a threshold length repeat (~35 pure repeats), slippage 
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can occur resulting in moderate expansion. Replication of larger repeats leads to hyperexpansion. 
DNA mismatch repair mechanisms likely play a role in correcting errors caused by slippage, since 
defects in mismatch repair lead to an increased of simple sequence repeat instability in both yeast 
and humans (for review, see[43]).  
There is no straightforward correlation between the degree of CAG instability and cell 
division rates (DNA replication), DNA damage (DNA repair and recombination), or disease-gene 
transcript levels (transcription) [44]. 
 The age-dependent repeat instability in somatic tissues, especially in terminally 
differentiated neurons, strongly suggests a relevant role for pathways that are independent of DNA 
replication. Transcription-induced repeat instability (Figure 1) can be modulated by several DNA 
repair proteins, including those involved in mismatch repair (MMR) and transcription coupled 
nucleotide excision repair (TC-NER). Transcription was also suggested as a possible cause for repeat 
instability, based on observations in four lines of transgenic mice that carried a portion of the 
huntingtin gene containing 55 CAG repeats [45]. In three of those lines, the transgene was 
expressed and was unstable, whereas in the fourth the transgene was silent and the repeat was 
stable. 
Very recent investigations have shown that genetic recombination is a powerful mechanism 
for generating massive expansions of trinucleotide repeat sequences. Several human genetic studies 
on patient materials reported haplotype analyses, especially related to myotonic dystrophy (DM) and 
the fragile X syndrome, which implicated gene conversion and/or unequal crossing-over (types of 
recombination) in genetic instabilities [46]. Studies in E.coli showed that the expansion of triplet 
repeats in vivo can occur by homologous recombination as shown by biochemical and genetic 
studies [47]. Gene conversion is an event in DNA genetic recombination, which occurs at high 
frequencies during meiotic division but which also in somatic cells. It is a process by which DNA 
sequence information is transferred from one DNA helix (which remains unchanged) to another DNA 
helix, whose sequence is altered.  This conversion was suggested as the mechanism responsible for 
trinucleotide repeat instability during repair in yeast [48]. Recombination mechanisms were also 
described in mouse models and clinical cases [46, 49].  
CAG repeat instability is behind some features of polyQ disorders and may also contribute to 
their pathogenic mechanism. 
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1.3 Polyglutamine pathogenic mechanisms  
  
 Several mechanisms have been implicated in polyglutamine toxicity, most of which 
are not mutually exclusive [50]. Here we will focus on three hypotheses: (i) disruption of 
proteostasis; (ii) transcriptional deregulation and (iii) mitochondrial impairment/oxidative stress.  
 
 1.3.1 Misfolded proteins and aggregation: disruption of proteostasis? 
 
 The presence of the expanded polyQ-stretch seems to confer novel properties to the 
mutant proteins, namely a tendency towards increased aggregation. Although protein aggregation is 
thought to be a central aspect of the biology of many neurodegenerative diseases, the role of two 
different types of aggregates in neurodegeneration is continuing to be elucidated. In polyQ disorders 
it is also generally accepted that aggregates or inclusion bodies are an important hallmark of 
polyglutamine diseases, and these aggregates are indeed found in patients’ brains, but the question 
remains: are the visible aggregates toxic or protective?  
Intranuclear inclusions were initially discovered in the first animal model of HD [16]. 
Interestingly, a correlation was observed between the length of the CAG repeat and the number of 
inclusions observed in the disease brains [51-53]. Other evidences suggested that aggregates could 
be protective to the cells, by stacking the toxic mutant proteins [54]. Indeed, protein aggregates are 
also naturally occurring species. An example are Marinesco bodies, which are eosinophilic 
ubiquitinated intranuclear inclusions found in pigmented neurons of the human substantia nigra and 
locus coeruleus as a result of the metabolism of normal aging neurons [55].  
 
 One way in which protein aggregates may harm neurons is by affecting their 
proteostasis. The hypothesis of cellular homeostasis disturbance suggests that the sequestration of 
chaperones and proteasome subunits into polyQ aggregates could result in an increased in general 
protein misfolding and reduced clearance of other crucial cellular proteins, leading to a proteostasis 
decline [56-58].  
 Several proteins are known to become trapped into these nuclear and/or 
cytoplasmic aggregates, such as ubiquitin, ubiquitin-like proteins, proteasome subunits, molecular 
chaperones and other polyQ-containing proteins [56, 58-60]. This suggests the involvement of the 
ubiquitin-proteasome degradation pathway in these pathologies, and also the activation of the heat 
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shock response machinery in order to either refold or degrade the mutant polyQ proteins. The 
mislocalization of chaperones and proteasome subunits may contribute to the progress of the 
disease. Molecular chaperones were shown to associate with the aggregates only transiently and to 
move freely [61]. However, the proteasome appears to be permanently recruited into polyQ 
aggregates and to be functionally impaired [62], which can interfere with the degradation of other 
proteins [63]. Proteasome inhibition might also increase the intracellular load of misfolded, oxidized, 
or otherwise damaged proteins, thereby causing neuronal toxicity. The consistent presence of 
normal ataxin-3 in NIs could reflect a biological feature of wild-type ataxin-3, which is translocated 
into the nucleus under pathological conditions and participates in the formation of aggregates [64]. 
    
 
 1.3.2 Transcriptional deregulation 
 
 Transcriptional alteration is another unifying feature of polyQ disorders [36, 65-69]; 
however, the relationship between polyQ-induced gene expression deregulation and the ongoing 
degenerative processes remains unclear.  
 More than 20 nuclear proteins relevant to transcription are known to interact with 
polyglutamine disease associated-proteins [65]. Mutant polyQ proteins have been shown to interact 
abnormally with proteins involved in the transcription machinery, namely the CREB-binding protein 
(CBP), p300/CREBBP associated factor (PCAF), TATA-binding protein (TBP), TAFII130, and SP1 
[65, 69]. Overexpression of some of these transcription regulators was shown to overcome polyQ 
toxicity, both in vitro in cellular models for MJD, SBMA, and HD [66, 70] as well as in vivo in a polyQ 
model in Drosophila [67]. This suggests an important role for transcription deregulation in polyQ 
pathogenesis. 
 Proteins that interact with polyglutamine disease associated-proteins are distributed 
around the core transcription machinery, which is now known to exert DNA methylation, histone 
acetylation and RNA modification simultaneously (see review [71]). CBP has attracted attention 
because CBP is a representative coactivator that possesses HAT (histone acetyltransferase) activity 
and interacts with numerous transcription factors, and its abnormal binding to disease proteins 
should affect the expression of a wide range of genes rather than that of a specific gene. Several 
polyQ-protein interactors have acetyltransferase activity. Acetylation of histones relaxes the DNA 
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structure promoting transcription, whereas hypoacetylation represses gene activity [72]. The 
equilibrium of histone acetylation/deacetylation is controlled by histone acetyltransferases and 
deacetyltransferases (HDACs). Thus, polyQ proteins may be toxic by their direct inhibition of the 
acetyltransferase activity of transcription regulators, leading to diminished gene expression. In fact, 
treatment of Drosophila and mouse models of HD with HDAC inhibitors has been shown to 
ameliorate the disease phenotype and to decrease cell degeneration, with the increase of histone 
acetylation and consequent transcription activation [73-75]. 
  
 1.3.3 Mitochondrial impairment/oxidative stress 
 
 The mitochondria has numerous important functions in the cell, however the 
mitochondrial respiratory chain is also one of the major sources of damaging free radicals in human 
organism, and these free radicals destroy cellular macromolecules, including DNA, lipids and 
proteins [79]. Mitochondrial dysfunction causes a decrease in ATP production, oxidative damage and 
induction of apoptosis, all of which are involved in the pathogenesis of several disorders [76-77]. 
They all share the common features of disturbances in the buffering capacity of mitochondrial Ca2+, 
ATP or reactive oxygen species (ROS) metabolism [78].  
   
 It has been proposed that mitochondrial impairment may be a major triggering 
factor of neurodegenerative diseases [80-81]. It is not clear what is the primary initiating event in the 
pathogenesis of each of these neurodegenerative disorders, but it seems that oxidative damage 
could constitute a critical factor in the propagation of injuries of the different cellular systems 
affected in most of them [82]. 
 A perturbation in the mitochondrial function leads to an ionic imbalance, calcium 
overload and ultimately, ATP depletion (Figure 1.1). If the energy supply of the cell drops 
dramatically, necrotic cell death will ensue. A mild or gradual energy disturbance may also lead to 
the release of proapoptotic factors, particularly cytochrome c from the mitochondria, and an 
apoptotic cascade is initiated as well. Excessive Ca2+ accumulation has deleterious effects, leading to 
the oxidative damage of different molecules with the resulting triggering of an apoptotic cascade. In 
addition, it should not be forgotten that non-excitable cells, such as astrocytes and microglia, are 
also strongly dependent on the intracellular Ca2+ concentration and Ca2+ signaling to maintain their 
normal function.  
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The cellular processes occurring during normal ageing are to some extent similar to those 
involved in the pathomechanism of neurodegenerative disorders, also leading to age-dependent 
impairment of mitochondrial function, for instance the appearance of mutations in mitochondrial 
DNA. A main difference may be that the metabolic dysfunction in the “normal” ageing brain is 
distributed in a random fashion, while in neurodegenerative disorders, specific causes and cellular 
disturbances are superimposed upon the age-dependent decrease of the homeostatic reserve, and 
these together attack specific structures of the CNS [83].  
 
1.4 Neuropathology and neuron-specific toxicity in polyglutamine disorders  
 
 The cause of neuron-specific dysfunction is a major unanswered question in the 
PolyQ field and, as such, is an active area of research.  
Several studies demonstrated that this neuronal-specificity is not due to the abundance of 
polyQ  proteins since they are ubiquitously expressed [3-4] (Figure 1.1) and must not be related to 
expression levels of those proteins before or after disease onset [84]. Similar expression levels of 
wild-type and mutant proteins were also shown in animal models and patients [85].  Another 
hypothesis put forward to explain this selective neuron dysfunction was the heterogeneity of polyQ 
length due to somatic mosaicism, resulting in loss of neurons with higher CAG repeats and survival 
of those neurons with less CAG-repeat length. This phenomenon was described for some of these 
diseases, but upon a more detailed analysis, no correlation with selective brain pathology was found 
[31, 37, 85]. Previous work from our lab also demonstrated, by screening the brain pathology and 
determining the CAG-repeat length in several brain areas (affected and spared) that there was no 
correlation between somatic mosaicism pattern and pathology in MJD. However, this finding could 
be a result of the technique used, since a gross dissection of the brain areas was performed. Also, in 
MJD patients, this kind of studies might be impaired by the use of post-mortem tissue in which 
surviving cells are those analysed. A third possibility is that in susceptible neurons, misfolding and 
aggregation could be prompted by cell-specific proteolytic events that release a polyQ-containing 
fragment [86] or by aberrant targeting of polyQ proteins to the nucleus only in certain cells [87]. 
Finally, specific interacting proteins are likely to contribute to selective vulnerability. For instance, 
certain interacting proteins may bind to disease associated-proteins in a way that promotes 
misfolding and aggregation, as was demonstrated for the huntingtin interacting proteins, SH3-
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containing Grb2-like protein (SH3GL3) [88] and Rhes protein [89]. Other specific interacting proteins 
are likely to influence events downstream of misfolding, through mechanisms that are linked to the 
specific normal functions of the disease proteins. Thus, in each disease, a subset of specific 
interacting proteins may bind less or more avidly to the mutant protein, thereby altering physiological 
or biochemical properties of one or both proteins. The susceptibility of a neuron to the downstream 
effects of the mutant protein would depend, in part, on the particular interacting proteins it 
expresses. The ataxin-1 interacting protein LANP (cerebellar leucine-rich acidic nuclear protein) is 
just one of a number of identified interacting proteins that may contribute in this manner to selective 
vulnerability [90]. 
 Extensive efforts are ongoing to understand how polyQ tracts may mediate neuron-
specific degeneration. If the toxic gain-of-function conferred by extremely large polyQ expansions 
results in non-specific neurodegeneration, pathogenesis caused by more moderate polyQ expansions 
may be susceptible to modification. Protein context is one factor that modulates polyQ pathogenesis 
and by doing so, it may contribute to the specific pathology observed in each CAG-repeat disease.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1.  CAG-repeat neurodegenerative 
diseases display unique neuropathology 
despite a common toxic motif. This schematic 
diagram identifies the major sites of neuronal 
loss in each disease. Dark red indicates 
severe or selective neuronal loss; half-tone red 
indicates moderate or variable cell loss. The 
circles in the cerebellar cortex represent 
Purkinje cells. AH, anterior horn; Cer, 
cerebellar cortex; C/P, caudate/putamen; 
Ctx, cerebral cortex; DN, dentate nucleus; GP, 
globus pallidus; LCN, lateral cuneate nucleus; 
PN, pontine nucleus; RN, red nucleus; SN, 
substantia nigra; STN, subthalamic 
nucleus;VL, ventrolateral thalamic nucleus; V, 
VI, VII, and XII, cranial motor nuclei. Figure 
adapted from [3]. 
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1.5 Cell death mechanisms 
 
 The relevance of cell death in neurodegenerative disorders is still a controversial 
topic, mainly because synaptic loss and electrophysiological abnormalities typically precede cell loss 
in these diseases. In addition, in chronic neurodegenerative diseases, cell death occurs over 
decades whereas the single cell suicide program is known to be executed within a few hours and the 
dead cells rapidly disappear [91-92].  
 Much of the attention in the cell death field has been drawn in recent years to a 
major cell death pathway apoptosis, which is often used as a synonymous of programmed cell 
death. The elucidation of additional programmed cell death pathways is gradually changing this 
notion. According to a recent classification, eight different types of cell death were delineated [93] 
and some researchers describe as many as 11 pathways of cell death in mammals, 10 of which 
appear to be programmed [94]. These pathways can be broadly divided into two main groups: 
apoptotic and non-apoptotic (see review [13]). 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3. Molecular pathways of programmed cell death (PCD) operating in 
misfolding/aggregation diseases.  
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Apoptosis vs Necrosis 
 
 Apoptosis, also referred to as type I programmed cell death, is the most well defined 
type of cell death pathways, both morphologically and biochemically, occurring by a caspase 
cascade. It is characterized by membrane blebbing, cytoplasmic shrinkage and reduction of cellular 
volume (pyknosis), as well as condensation of the chromatin, and fragmentation of the nucleus 
(karyorrhexis), all of which ultimately lead to the formation of apoptotic bodies, a prominent 
morphological feature of apoptotic cell death [93]. As apoptosis typically does not induce 
inflammation or tissue scarring, it is well suited for a role in normal cell turnover during 
embryogenesis and in adult tissues [95].  Caspases are a family of proteins that are one of the main 
effectors of apoptosis. Their activation is a hallmark of apoptosis. Based on their function, the 
caspases can be classified into three groups: inflammatory (caspases 1, 5, 11, 12, 13, 14, involved 
in inflammation), initiator caspases (2 and 8 which contain a death effector receptor and 2 and 9 
that possesses recruitment and activation domain) and finally effector caspases (3, 6, and 7, which 
are the executers) [96-97]. Recent estimates suggest that apoptosis deregulation contributes to 
about half of all the major medical illnesses for which adequate therapy or prevention is currently 
lacking [98].  
 The type of cell death in neurodegenerative disorders remains a matter of 
controversy, and it is possible that both apoptotic and nonapoptotic cell death coexist in the brains of 
affected patients [91]. Knock-out mice models have elucidated the researchers about the cell death 
pathways occurring in mammals and have revealed a prominent neuronal apoptosis defect in mice 
defective for caspase-3, caspase-9 and Apaf-1, suggesting that this pathway of caspase activation is 
important in regulating neuronal cell death in the developing brain [99].  
 Alzheimer’s, Huntington’s, Parkinson’s and Prion diseases, as well as ALS, all have features 
of misfolded proteins. These disturbances can cause accumulation of unfolded proteins in the ER, 
triggering an evolutionarily conserved response termed the unfolded protein response (UPR) [100-
101]. It has been proposed that these protein aggregates exhaust cellular proteasome activity in a 
failed attempt to degrade them, resulting in a secondary accumulation of misfolded proteins in the 
ER, thereby triggering ER stress (see review [102]. The UPR controls the levels of molecular 
chaperones and enzymes involved in protein folding in the ER. ATF6 located at the ER membrane is 
one of the candidates for the UPR-specific transcription factor [14]. Grp78/Bip (Bip) protein is the 
chaperone that increases protein folding in the ER lumen [15]. Upon induction of ER stress, ATF6 is 
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processed and the processed cytoplasmic region translocates into the nucleus and activates 
transcription of the endogenous Bip gene [14]. When these stress signals are unable to rescue cells, 
the apoptotic pathway is activated. Caspase-12, which is located at the outer layer of the ER, is one 
of the apoptotic pathways of ER stress-mediated cell death [16-17].  
 
 Necrosis has traditionally been considered an unregulated, energy- independent 
form of cell death, and has been well-characterized in a wide range of pathologic states. Extensive 
failure of normal physiological pathways that are essential for maintaining cellular homeostasis, such 
as regulation of ion transport, energy production and pH balance can lead to necrosis. Necrosis is 
characterized morphologically by vacuolation of the cytoplasm, breakdown of the plasma membrane 
and induction of inflammation around the dying cell due to the release of cellular contents activating 
the resident phagocytes and attraction of leucocytes into the necrosis area [103][18]. A classic 
example of necrotic conditions is ischemia that leads to a drastic depletion of oxygen, glucose, and 
other trophic factors and evokes massive necrotic death of endothelial cells and nonproliferating 
cells of surrounding tissues. Necrosis can be induced by microbial infections, neuronal excitotoxins, 
or ROS [104]. 
Many human tumors carry mutations that inactivate apoptotic pathways. Inactivation of 
apoptosis allows tumor cells to proliferate beyond normal homeostatic control. Necrosis represents 
an alternative pathway for these cells to be eliminated. The inflammatory component of necrotic 
death has the potential advantage of stimulating an immune response that could increase the 
efficiency of tumor cell death [105]. The balance between apoptotic and necrotic cell death may be 
modulated to potentiate a patient's immune response to a tumor. 
 Adult neuronal death also occurs by necrosis, an unregulated cell death that is the 
direct result of external insults such as physical injury, energy depletion, toxic insults, hypoxia 
and/or ischemia. Necrosis of adult neurons is independent of caspases, and although the precise 
molecular mechanism underlying this type of cell death is unknown, it might be mediated by 
increases in intracellular calcium, which activates calpains and cathepsins (cytosolic calcium-
activated cysteine proteases), leading to degradation of cytoplasmic proteins [106].  
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Another way to die: autophagic programmed cell death 
 
 Autophagy is an evolutionary conserved and genetically controlled turnover of 
cellular constituents that occurs in all eukaryotic cells [107]. Autophagy is defined morphologically 
by the appearance of numerous cytosolic autophagosomes, which are formed by the assembly and 
expansion of double layered, membrane bound structures of unknown origin around whole 
organelles and isolated proteins. The origins of autophagosomes are difficult to determine because 
they contain a mixture of markers from the ER, endosomes and lysosomes. The autophagosomes 
encapsulate cytosolic materials and subsequently dock and fuse with lysosomes or other vacuoles, 
resulting in the degradation of their contents [108].  
Autophagic cell death is thought to represent an alternative pathway to cell death when 
apoptosis is impeded, but there are indications that autophagic cell death and apoptosis are not 
mutually exclusive death pathways, and can cross talk with each other [108]. Evidences for this 
purpose are (i) the fact that apoptosis regulating molecules such as Bcl 2, Bcl xL, Bax and Bak were 
implicated in the regulation of autophagy, both independently and through interaction with Beclin 1 
[109-110] and (ii) that some of the endonucleases that take a part in apoptosis associated DNA 
fragmentation may originate in lysosomes [111].  
Autophagy impairment has been reported in neurodegenerative diseases including 
Parkinson, Huntington, and Alzheimer diseases [112-114]. In these diseases, the pathological 
accumulation of autophagosomes/ autophagosome-like structures and abnormalities in the 
endosomal-lysosomal pathway were documented by electron microscopy (EM) in human 
postmortem brain tissue [115-119]. 
 While the role of autophagy in neurodegenerative diseases is far from being 
understood, the available data indicate it plays an integral role in the cellular response to 
intracellular protein aggregation common to these diseases. The effect of autophagy in neurons 
during disease can be broadly divided into two classes: autophagosomal degradation is either 
impaired or excessively activated, leading to an apparent disruption of the intracellular organelle 
organization and accumulation of autophagosomes in neurons over long periods of time. 
 Autophagy plays a crucial role in maintaining neuronal homeostasis through 
clearance of defective organelles and unfolded/aggregating proteins.  
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1.6 Machado-Joseph Disease  
 
 Machado-Joseph disease (MJD), also known as Spinocerebellar Ataxia 3 (SCA3), is 
the most common autosomal dominant ataxia worldwide [24]. The disease was first described in 
families from the Azores Islands, being reported some years later in other countries and in families 
with no Portuguese ancestrality. This late-onset disorder was first described as an autosomal 
dominant ataxia in William Machado’s family, and thus named Machado disease [120]. In the same 
year, another case was reported (in the Thomas family) with similar clinical symptoms, and this 
disease was entitled as “Nigro-spino-dentatal degeneration with nuclar ophthalmoplegia” [121]. 
Later on, in 1976 was described a “particular type of autosomal dominant hereditary ataxia” in the 
family of Antone Joseph, which was designated as Joseph disease [122].  
Two years later, after an intensive study in Azorean families and regarding the common 
features of the three families described above, a new “autosomal dominant system degeneration in 
Portuguese families of the Azores Islands” was introduced [123]. In the 80’s, this disease was 
named Machado-Joseph disease (MJD) and some clinical criteria for diagnosis were introduced 
[124]. The prevalence of this disease was from the beginning thought to be the highest among 
people of Portuguese/Azorean descent. For immigrants of Portuguese Azorean ancestry in New 
England, the prevalence was described to be around 1:4000. In Portugal the prevalence of 
Machado-Joseph disease is 3,1:100,000 (P.Coutinho, Personal Communication), with clusters in 
several mainland regions, reaching a value of 1:140, on the small Azorean island of Flores [125].  
Later, however, researchers, based in DNA studies, have identified MJD cases in many 
ethnic backgrounds. Its relative frequency among the spinocerebellar ataxias is higher in Portugal 
(49%), China (49%), Brazil (44%), the Netherlands (44%), Japan (43%), and Germany (42%); its 
relative frequency is lower in France (33%), the United States (21%), and Australia (12%); and it is 
rare in the United Kingdom (5%), India (3%), and Italy (1%) [126-137].  
 
 
 1.6.1 Clinical definition 
 
 MJD patients suffer from a progressive neurodegenerative disorder appearing more 
frequently between the ages of 20 and 50 years, in which the intellect is preserved [123]. The 
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preservation of cognitive function is a key feature of MJD in its differential diagnosis among the vast 
group of spinocerebellar ataxias. MJD is characterized by motor uncoordination and weakness in the 
arms and legs, spasticity, gait ataxia, difficulty with speech and swallowing, altered eye movements, 
double vision, and frequent urination. Some patients have dystonia (sustained muscle contractions 
that cause twisting of the body and limbs, repetitive movements, abnormal postures, and/or rigidity) 
or symptoms similar to those of Parkinson's disease. Others have twitching of the face or tongue, or 
peculiar bulging eyes due to lid retraction. The severity of the disease is related to the age of onset, 
an earlier onset being associated with a more severe and rapidly progressive form of the disease. 
Symptoms can begin any time between early adolescence and old age up to 70 years of age [125]. 
MJD is also a progressive disease, meaning that symptoms get worse with time. Life expectancy 
ranges from the mid-thirties, for patients with severe forms of MJD, to a normal life expectancy for 
those with mild forms. For patients who die early from the disease, the cause of death is often 
aspiration pneumonia due to immobility and poor coordination of swallowing and breathing. The 
clinical spectrum of SCA3 is highly pleomorphic and led to the definition of four clinical sub-
phenotypes: type I, characterised by the dominance of pyramidal and extrapyramidal anomalies, in 
addition to ataxia and other signs, with an early age-at-onset and fast progression; type II, with 
typical cerebellar ataxia, progressive external ophtalmoplegia and pyramidal signs appearing at an 
intermediate age; type III, with late onset and slow progression of peripheral signs, such as loss of 
proprioception and muscle atrophies; and type IV, the rarest, characterised by the presence of 
Parkinsonic signs, associated to the core clinical features [123-124, 127]. 
 
 1.6.2 Pathology  
 
 Pathological examination of post-mortem MJD patients’ brains showed a 
depigmentation of the substantia nigra, a considerable atrophy of the cerebellum, pons, and medulla 
oblongata, as well as in motor cranial nuclei [3, 129]. More recently, it was shown that all the 
precerebellar nuclei and the thalamus were also affected in MJD patients [126, 130].  In addition, in 
the majority of these patients the post-mortem brain weight is lower than that of individuals without 
medical histories of neurological or psychiatric diseases [131]. 
Intracytoplasmic inclusions although, observed to a lesser extent than intranuclear ones, are 
found in MJD patients’ brains [128], constituting a pathological feature of MJD. In vivo and in vitro 
studies suggests that disease protein ataxin-3 accumulates in ubiquitinated intranuclear inclusions in 
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neurons of affected brain regions [6, 19-20]. Several MJD mouse models were generated in the last 
years and nuclear and /or cytoplasmic aggregates were observed in the mice brains [21-25]. 
 
 1.6.3 Genetics 
 
 The fact that MJD is a hereditary autosomal dominant disease means that the 
presence of the mutation in one single allele is sufficient to cause the disease. This implies that an 
affected individual has a 50% chance of passing the disease on to their offspring. Like in other CAG 
repeat diseases the phenomenon of anticipation is quite common. The children of affected parents 
tend to develop symptoms of the disease earlier in life, have a faster progression of the disease and 
experience more severe symptoms. A longer expansion is associated with an earlier age-of-onset and 
a more severe form of the disease. However, it is impossible to predict precisely the course of the 
disease for an individual based solely on the repeat length. Many years after the first description of 
the disease, its causative gene was described and mapped in the chromosome 14.q32.1 [132]. The 
MJD1 gene (later named ATXN3) was cloned one year later, and the authors observed that the 
mutation (expansion) of the CAG tract was only present in patients [7]. This knowledge allowed the 
establishment of the molecular diagnosis of MJD, based on the determination of the CAG repeat 
length, and the consequent confirmation of the disease in families of different origins [24, 133]. The 
genomic structure of the ATXN3 gene and the subsequent knowledge of the number and size of 
exons and introns was only established in 2001. The gene has around 48 Kbp and was described to 
contain 11 exons, the CAG tract being in exon 10, and to encode at least four different transcripts 
with variable sizes: 1.4, 1.8, 4.5, and 7.5 Kb, probably due to differential splicing and 
polyadenylation signals. Very recently 56 additional splicing variants of ATXN3 gene, some of which 
observed only in MJD patient’s, were reported [134-135]. The biological relevance of these variants 
remains to be determined. In the brain, ATXN3 is preferentially transcribed in neurons although low 
levels are also present in glial cells. Most importantly, neurons susceptible to cell death in 
MJD/SCA3 express ATXN3, although not selectively. Also, ATXN3 mRNA levels do not differ between 
controls and patients and are not correlated with the clinical severity or repeat length [136].  
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 1.6.4 ATXN3 gene product: ataxin-3 (ATXN3) protein  
 
 Ataxin-3 has an approximate molecular weight of 42 kDa in normal individuals, but 
is significantly larger in affected patients, confirming that the expanded CAG repeat is translated into 
a polyQ stretch. This polyQ tract is located in the C-terminus region that is variable in length, 
depending on the isoform, and whose expansion is intrinsically related with MJD. [7] 
 Different isoforms of ataxin-3 have been described: isoform 1 (NP_004984) has 
361 aa, with a hydrophilic C-terminal and corresponds to the clones MJD1-1 and MJD5-1 [137]; 
isoform 2 (P54252) has a distinct C-terminal region when comparing with the first one and it has a 
hydrophobic nature. It is formed by 365 aa and matches the MJD2-1 clone [137]; the third variant, 
MJD1a (S50830) contains 349 aa (it lacks 16 aa within the C- terminus region comparatively to 
isoform 2, due to a premature stop codon [7]. Finally, the variant 4 (NP_1093376) contains less 55 
aa than isoforms 1 due to the lack of exon 2 in the H2 clone [134]. This ATXN3 variant lacks the 
catalytic aminoacid (Cys14), essential for ATXN3 deubiquitylating in vitro activity against poly-
ubiquitin chains [135, 138]. The human ataxin-3 protein has a conserved N-terminal josephin 
domain (1-198 aa) containing the putative catalytic triad aminoacids cysteine (C14), histidine 
(H119) and asparagine (N134). The josephin domain, which derives from the name of the disease, 
is followed by two or three (in isoforms 1 and 4) ubiquitin-interacting motifs (UIMs) and the polyQ 
stretch and also has a conserved nuclear-localization signal (NLS). Similarly, 6 putative nuclear 
export signal (NES) sequences were found within the ataxin-3 primary structure [135]. Considering 
the splicing variants recently reported [26], more ataxin-3 isoforms could exist, and given that fact, is 
still unclear which ones would be more relevant in the disease context.  
 Ataxin-3 is found in the genomes of several species, ranging from nematodes to 
human, and including plants [138]. It possesses a globular N-terminal domain with a sequence 
motif named Josephin (residues 1-198 in the human protein). The sequence of the C-terminus, 
which contains low complexity sequences, is less conserved among species.  
The search for protein motifs suggested that ataxin-3 might be an ubiquitin-binding protein 
[139]. Functional assays in vitro supported this function and showed predominant binding to K48-
linked tetra-ubiquitin through its ubiquitin interaction motifs (UIM) located near the polyglutamine 
domain [60, 140-141]. A crucial breakthrough in the understanding of ataxin-3 function was the 
discovery of its DUB activity in vitro [140, 142], however the biological consequence of this function 
hasn’t been characterized extensively yet and the cellular substrates of ataxin-3 remain unknown. 
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 Histone ubiquitylation results in heterochromatin relaxation and assembly of transcription 
complexes on the promoter, and ubiquitylation of transcription factors enhances their transcriptional-
activation function (see review [143]. Therefore, deubiquitylating enzymes as ataxin-3 can also 
modify transcriptional regulation through the removal of ubiquitin from histones. A role of ataxin-3 in 
proteasomal protein degradation has been supported by the identification of its interaction partner, 
valosin-containing protein (VCP) [142]. Recently, several reports have been described interactions 
between ataxin-3 and numerous other proteins, implicating it in various cellular functions and 
pathways [144-146].  
 
 
1.7 Different mouse models for the same disease  
 
 Although there is no treatment available at present to cure or delay the onset of 
MJD, mouse models have been generated to facilitate the understanding of the disease and the 
development of a therapy. Mice are the preferred animal model because they are small and easy to 
genetically manipulate and can be generated in relatively large numbers, kept in a controlled 
environment, and used for invasive procedures. Being mammals, they have important genomic, 
anatomical, and physiological similarities to humans [147]. The technical problems encountered in 
the use of patient brain tissue, such as autolysis caused by long postmortem delays, can be avoided 
using mouse models. 
 
 The first transgenic mouse model of MJD was generated using truncated and full-
length cDNAs of the ATXN3 gene, with the L7 promoter directing expression specifically in Purkinje 
cells (poorly affected in MJD). In these constructs, the cDNA encoded for Q79C, Q79, Q35C 
(truncated forms with or without the C-terminal) or MJD79 (full-length context). The transgenic mice 
expressing truncated forms (Q79C, Q79) of the protein with an expanded polyQ tract showed an 
ataxic phenotype, whereas the animals expressing the full-length protein (MJD79) or a polyQ length 
present in human control individuals (Q35C) did not reveal any characteristic symptom of the 
disease.  The onset of the symptoms in the affected animals was around 4 weeks of age and the 
strong ataxic phenotype was more prominent in animals with a higher copy number of the 
transgene. Histological analysis of these ataxic mice brains showed an atrophic cerebellum and 
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massive loss of Purkinje cells. This work showed that the expanded polyglutamine tract is 
responsible for neuronal loss and degeneration [15].  
 
 Some years later, another mouse model was created in an attempt to properly 
mimic the temporal and spatial expression of the human disease gene, using yeast artificial 
chromosome (YAC) constructs carrying the full-length ATXN3 gene with expanded polyglutamine 
tracts, containing all the enhancers and long-range regulatory elements needed for cell-specific 
expression at physiological levels. Two additional genes were also part of the cloned genomic region. 
Homologous recombination in the yeast host was used to generate three YAC constructs 
with 15, 76 and 84 repeats, corresponding to the human wild-type, intermediate and early-disease-
onset MJD alleles, respectively. The mice carrying expanded alleles showed abnormal gait, tremor, 
hypoactivity, limb clasping, an inability to correct geotaxis, reduced grip strength, abnormal toe pinch 
responses and progressive loss of weight. These symptoms aggravated with repeat length and with 
the gene dosage. Regarding the onset of the disease, homozygous mice showed an earlier onset, 
with faster and worse disease progression. Analysis of brain sections showed degeneration, mild 
gliosis of the dentate and pontine nerve nuclei (affected in MJD patients) and increased number of 
reactive astrocytes in the cerebellum. Ubiquitinated nuclear inclusions were also shown in 
symptomatic mice [148]. These mice are representative of MJD and can be a valuable resource for 
the detailed analysis of the roles of repeat length, tissue specificity and level of expression in the 
neurodegenerative processes underlying MJD pathogenesis and could also be used to test 
therapeutic strategies. However, for this later purpose, their phenotype may be considered too mild. 
 
 In 2004, a third mouse model of MJD was published. This transgenic mouse 
expresses human mutant (Q71B and Q71C) or normal (Q20) ataxin-3 MJD1a under control of the 
mouse prion promoter, driving expression throughout the brain and spinal cord. Homozygous but 
not heterozygous (Q71B and C) animals displayed a phenotype that included progressive postural 
instability, gait and limb ataxia, weight loss, premature death, neuronal intranuclear inclusions, and 
decreased TH-positive neurons in the substantia nigra. The phenotype manifested only when the 
mutated protein was expressed above a critical concentration, i.e., only in their Q71C line. The 
heterozygous animals were indistinguishable in appearance and behavior from wild-type mice. This 
line also had problems in breeding, since homozygous animals were infertile. Brains from affected 
Q71-expressing transgenic mice contained an abundant mutant ataxin-3 putative-cleavage fragment 
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(Fragment ~35kDa), which was scarce in normal Q20 transgenic mice. Reactivity of the Fragment 
with several antibodies and analysis of co-migration with truncations of mutant ataxin-3 revealed that 
it contained C-terminal residues spanning from amino acid 221, including the polyglutamine 
expansion. The Fragment was also shown to be more abundant in the two affected brain regions in 
MJD patient’s post-mortem (dentate nuclei and substantia nigra). Thus these authors developed a 
new murine model for mutant ataxin-3 toxicity and identified a putative cleavage fragment of the 
disease protein that appeared to be cytotoxic above a critical concentration [149]. 
 
 In the last few years, more mouse models were generated and other clues have 
arisen from these models. In 2007, a mouse model was generated using full-length ataxin-3 
constructs (isoform 1, clone MJD1-1, with a third UIM at the C-terminus) containing 15, 70, or 148 
CAG repeats under control of murine prion protein promoter. A nuclear signal (NLS) was also 
introduced as well as a nuclear export signal (NES) to transport ataxin-3 into the cytoplasm. 
Transgenic mice carrying 70 CAG repeats revealed a severe and rapidly progressive phenotype 
(tremor, wide-based hindlimbs to stabilize the body in a resting position as well as markedly reduced 
activity and grooming, resulting in a disheveled appearance) displaying a large number of NIIs and 
dying prematurely. This study demonstrated, not unexpectedly, that both the size of the expanded 
CAG repeat length and the level of transgene expression are of major importance for disease onset 
and disease progression in mice. Mice with a less strong expression of ataxin-3 with 70 CAG repeats 
developed a milder phenotype than lines with a stronger expression. Similar, transgenic mice but 
with 148 CAG repeats merely survived the first months and had major problems to produce 
offspring, whereas mice with stronger expression of this transgene died very early without producing 
any offspring. More important, the artificially induced nuclear localization of ataxin-3 with 148 
polyglutamine repeats accelerated and intensified the phenotype of transgenic mice even further, 
whereas the addition of a nuclear export signal ameliorated the phenotype. This model thus 
demonstrated that nuclear localization of ataxin-3 plays an essential role in MJD [150].  
 
 In 2008, another transgenic mouse model was created using cDNA of human wild-
type ataxin-3-Q22 or disease-causing ataxin-3-Q79 (ataxin-3 mjd1a isoform) under the control of 
mouse prion protein promoter [151]. Mice from two ataxin-3-Q79 transgenic lines displayed various 
symptoms of motor dysfunction with an onset age of about 5–6 months, and the severity of 
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neurological phenotypes progressively increased in the following months. The symptoms included 
forelimb clasping, impaired motor coordination and shorter latency to fall in the rotarod behavioural 
test, less activity, incorrect body posture, ataxic gait, reduced weight and reduced pelvic elevation. 
Authors also found ubiquitinated nuclear inclusions in the neurons of dentate nucleus, pontine 
nucleus and substantia nigra (as in human MJD patients). Some stainings demonstrated a mild 
reduction in the number of neurons of the cerebellar dentate nucleus, granular, molecular and 
Purkinje cell layers. These mice showed a motor dysfunction, although there was an absence of cell 
death, suggesting that instead of neuronal loss, mutant ataxin-3 causes neuronal dysfunction. In 
order to test the involvement of neuronal deregulation in this model, the authors performed a 
microarray analysis in the cerebellum of the mice where they found a variety of deregulated gene 
expression, down (genes involved in glutamatergic transmission, transcription factors, genes 
involved in Ca2+ signalling, heat shock proteins, GABA receptors) or upregulated (pro-apoptotic 
proteins, proteasome subunits, RNA polymerase subunits). 
 
 Finally, also in 2008, a different model was generated; these authors used rats 
instead of mice, and take advantage of the lentivirus’ (LV) features. cDNAs encoding the human wild-
type ataxin-3 (Atx3-27Q) or mutant ataxin-3 (Atx3-72Q,  isoform mjd1a) were used. Lentiviral vectors 
encoding human wild-type (Atx3-27Q) or mutant ataxin-3 (Atx3-72Q) were stereotaxically injected into 
the substantia nigra, cortex or striatum of the brain of these rats. Pathological changes were 
observed in the substantia nigra, such as nuclear inclusion bodies in animals injected with mutant 
ataxin-3 cDNA. These nuclear inclusions co-localized with ubiquitin and α-synuclein. Authors also 
tested the involvement of ataxin-3 in neuronal dysfunction, by measuring two markers of 
dopaminergic neurons, the tyrosine hydroxylase (TH) and the vesicular monoamine transporter 2 
(VMAT2). They found a loss of TH’ and VMAT2’ positive neurons. A reduction of TH 
immunoreactivity was also observed in the striatum of animals injected with LV encoding mutant 
ataxin-3, suggesting dysfunction of the TH nigro-striatal projecting fibers.  
 In order to investigate the involvement of striatum in MJD, pathological analysis was 
performed in this brain region, and a condensation of the cell nucleus, loss of neurons, 
condensation of the internal capsule of the striatum and fluorojade B (cell death marker) positive 
cells was observed [152].  These results indicate that brain delivery of mutant ataxin-3 with lentiviral 
vectors provides a new genetic model of MJD which may help elucidate the molecular mechanism of 
mutant ataxin-3 toxicity and may facilitate the evaluation of new therapeutic strategies. 
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 In our lab, we also generated a novel transgenic mouse model, using a human 
cDNA (isoform 1, MJD1-1 clone)) carrying the repeat tract coding for 83 polyglutamines, under 
control of the pCMV (cytomegalovirus) promoter, a strong and general promoter. From two different 
microinjections two female founders (background FVB/N) were obtained, A and B. These two 
founders were able to transmit the transgene through the generations leading to the establishment 
of two transgenic mice lineages that were backcrossed with C57Bl/6 mice 9 and 7 times for the 
creation of experimental animal groups for lineage A and B, respectively (Silva-Fernandes, submitted 
for publication). 
 
 This novel transgenic mouse model for MJD has revealed some important features 
that recapitulate the disease. Namely, hemizygous transgenic animals developed a motor phenotype 
in agreement with the dominant feature of the disease; there was a correlation between CAG repeat 
length and disease manifestation; MJD transgenic mice displayed intergenerational instability and 
somatic mosaicism in different neuronal and non-neuronal tissues; MJD mouse brains showed 
neuronal atrophy in specific regions such as the thalamus, dentate nuclei, substantia nigra and the 
vestibular nuclei. Although the possibility existed that overexpression of ataxin-3 would give rise to 
some form of pathological consequences, no pathology was observed in homozygous transgenic 
mice from lineage B, which express similar levels of mutant AT3 to those of hemizygous animals of 
lineage A. Since the founder B carried a shorter CAG tract than founder A (83 vs 94 CAGs), this data 
allowed to us to conclude that at this level of expression of mutant AT3 the minimum CAG tract 
length to induce phenotype in transgenic mice was located between 83 and 94 CAG repeats. 
Behavioural studies revealed a number of findings in the mice from lineage A that differed from non-
transgenic and transgenic from lineage B. We found that hemi and homozygous animals of lineage A 
displayed an uncoordination phenotype. In lineage A, which manifests MJD-like symptoms it was 
possible to establish a phenotype-genotype correlation: animals with higher CAG repeat tract spent 
less time on the rod. Pathological examination of the brains of MJD transgenic mice with expanded 
(CAG)n alleles originated from founder A also showed atrophy and/or apparent cell loss in several 
areas, including the substantia nigra, thalamus, dentate and vestibular nuclei as well as astrogliosis 
in specific areas such as the vestibular nuclei and substantia nigra. This is a promising model for 
SCA3 since it mimics in many aspects the disease-like features and could also be useful for 
dissecting the initial cellular and molecular events in the pathogenesis of MJD.
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Chapter 2. Objectives 
 
 
Regarding the impact of neurodegenerative diseases in the society and bearing in mind that 
the “why and how” of these diseases are still unclear, we aimed to contribute for the 
characterization of a novel mouse model of MJD. Our specific goals were: 
 
1. To study the neuropathology of the CMVMJD1-1 transgenic mice; 
 
2. To map and screen the cell death mechanisms in the brain of this mouse model; 
 
3. To determine the CAG repeat instability pattern of the MJD transgenic mouse model, 
across generations, both in maternal and paternal meioses, in two genetic backgrounds (C57Bl/6 
and FVB/N);  
 
4. To analyse the degree of somatic mosaicism in distinct areas of the Central Nervous 
System and in peripheral tissues of MJD transgenic mice and correlate it with their observed 
pathological involvement. 
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Chapter 3. Brain pathology in MJD transgenic animals 
 
 
3.1 Background 
 
 In MJD only restricted populations of neurons are affected even though ataxin-3 is 
ubiquitously expressed in the central nervous system [59]. Since the first description of the 
neuroanatomical alterations observed in MJD patients [27-28] several studies has been published to 
better understand the pattern of central nervous dysfunction and/or degeneration [153][29-32].  
The initial studies suggested that central nervous neurodegeneration in SCA3 is restricted to 
the cerebellar dentate nucleus, the pallidum, the substantia nigra, subthalamic, red, and pontine 
nuclei, select cranial nerve nuclei and the anterior horn and Clarke’s column of the spinal cord [33-
34]. More recent studies allowed the identification of a more widespread degeneration in the CNS of 
MJD patients, including the cerebellar cortex, the thalamic nucleus, the vestibular and the 
oculomotor systems [130, 146].  
Pathoanatomical analysis of SCA3 brains helps to understand the structural basis of this 
neurodegenerative disease and offers explanations for a variety of disease symptoms. This better 
understanding of the neuropathology of the condition has implications for the treatment of SCA3 
patients and represents a basis for further biochemical and molecular biological studies aimed at 
deciphering the pathomechanisms of this progressive ataxic disorder.  
The cerebellum has been suggested to be a major target of degenerative processes in MJD 
[4, 156]. It receives somatosensory, somatomotor and oculomotor afferents from the neocortex, the 
brainstem and the spinal cord, and subsequent to cerebellar processing for the most part projects 
these data back to the neocortex and the vestibular nuclei via its cortical Purkinje cells, deep nuclei 
(fastigial, globose, emboliform, and dentate nuclei) and the thalamic ventrolateral nucleus [157-
160]. Owing to these anatomical connections the cerebellum is integrated into neuronal motor 
feedback loops which, via long descending corticonuclear and corticospinal projections, ultimately 
control the activity of premotor and motor neurons in the lower brainstem and spinal cord and thus 
it participates in the fine coordination of movements of the limbs, trunk, head and eyes. All these 
connections suggests that probably there are other brain areas and different subregions involved in 
this disease such as precerebellar nuclei (red, pontine, arcuate, prepositus hypoglossal, superior 
vestibular, lateral vestibular, medial vestibular, interstitial vestibular, spinal vestibular, vermiform, 
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lateral reticular, external cuneate, subventricular, paramedian reticular, intercalate, interfascicular 
hypoglossal, and conterminal nuclei, pontobulbar body, reticulotegmental nucleus of the pons, 
inferior olive, and nucleus of Roller) which has been recently demonstrated [161].  
In order to validate our transgenic MJD mouse model we studied the pathological features 
present in the transgenic mouse brains. We observed neuronal atrophy of some brain regions 
analysed, with the presence of dark neurons in the thalamus, dentate and pontine nuclei, 
astrogliosis in the vestibular nuclei and substantia nigra, and ataxin-3 positive-perinuclear 
aggregates, suggesting that this mouse model mimics some of the pathological findings observed in 
MJD patients. 
  
3.2 Materials and Methods 
 
DNA extraction and mouse genotyping 
 
For mouse genotyping, DNA was isolated from tail tissue using Puregene DNA isolation kit 
(Gentra systems, inc). For PCR genotyping, the primers TR1 (5’-GAA GAC ACC GGG ACC GAT CCA 
G-3’) and TR2 (5’-CCA GAA GGC TGC TGT AAA AAC GTG C-5’) were used to amplify the transgene 
(454 bp) and as an internal control of the PCR the mouse homologous Atxn3 gene was amplified 
(800 bp) using the primers mmMJD8 (5’-CAA AGT AGG CTT CTC GTC TCC T-3’) and mmMJD24 (5’-
AGT GCT GAG AAC ACT CCA AG- 3’). The fragments were amplified in a reaction mixture containing 
, buffer (10mM Tris-HCl, pH 8.3, 50 mM KCl) and 0.75 U of DNA Taq polymerase (Fermentas). PCR 
cycling conditions are as follows: 95ºC for 5 minutes followed by 35 cycles of denaturing at 95ºC for 
1 minute, annealing at 60ºC for 1 minute, extension at 72ºC for 1 minute and final extension at 
72ºC for 10 minutes. The PCR products were loaded on 1.5% agarose gels and electrophoresed at 
120 V for 1 hour. Gels were visualized with AlphaImager 2200 (AlphaInnotech) and analyzed 
densitometrically with the corresponding AlphaEase software. 
 
To discriminate between hemyzygous and homozygous transgenic mice a semi-quantitative 
PCR was performed, in which transgene amplification was performed using the TR1 and TR2 
primers described above. As a reference gene, an intronic fragment (546 bp) of the mouse 
homologous Atxn3 gene was amplified using the primers mmMJD89 5’ GCT AGC TAG AGC TAC TTA 
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TTG 3’ and mmMJD54 5’ GAC TCC AGA GAG CAC CTG 3’. Briefly, to determine the number of 
cycles in which the amplification was at the middle of the exponential phase, a sequential series of 
PCRs using both pairs of primers were performed for each lineage of transgenic mice as described 
above, differing only in the number of cycling times.  
 
Animals  
 
The C57Bl/6 and transgenic animals used in this study were all sacrificed by 
exsanguination and posterior perfusion using 100 mL of fixative solution (4% paraformaldehyde 
(PFA) in 0,1M phos
5.9 mL saline). The tail and the brain were collected and the brain was immersed in PFA 4% for 2 
days for posterior processing.  
 
Immunohistochemistry 
 
After two days in PFA 4% the brains were embedded in paraffin and sections were cut with a 
 
 
Slides with paraffin sections 4 μm thick were steamed for antigen retrieval and then 
incubated with GFAP antibody (1:500) or polyclonal antibody for ataxin-3 (1:40). A secondary 
antibody (anti-rabbit) was applied, followed by ABC coupled to horseradish peroxidase (Dako) and 
DAB substrate (Vector Laboratories). The slides were counterstained with hematoxylin according to 
standard procedures and analyzed under a microscope (Olympus) using visible light. For 
morphological brain analysis we performed hematoxylin&eosin and cresil violet staining. 
 
3.3 Results and discussion 
 
As shown in figure 3.1/3.2, pathological examination of the brains of middle age MJD 
transgenic mice with expanded CAG from lineage A showed neuronal atrophy in several areas, 
including the substantia nigra, thalamus, dentate and vestibular nuclei as well as astrogliosis in 
specific areas such as the vestibular nuclei, substantia nigra. These findings are in agreement with 
the pathological findings reported in MJD patients, where the degeneration involves neuronal loss 
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and gliosis and the commonly affected regions include the dentate and pontine nuclei, substantia 
nigra and vestibular nuclei [153, 165-167].  
Astrocytes are CNS cells that respond to injuries in the brain. The presence of mutated 
ataxin-3 may represent an insult and astrocytes are able to react. Astrogliosis is also characterized 
by rapid synthesis of GFAP intermediate filaments [154]. Increased astrogliosis in transgenic mice 
and absent in wild-type animal, may indicate this insult of ataxin-3, showing that mutated ataxin-3 is 
deregulating the tissue homeostasis.  
We observed shrunken cells with pyknotic or small nuclei in the transgenic animals but not 
in the wild-type, this morphology could be associated with dark neurons which are considered a 
manifestation of neuronal injury and although they are associated with various grades of damage 
their mode of formation is not yet clear. It has been suggested that the dark neurons may reflect 
early damage in the cytoskeleton such as microtubules or microfilaments [155].  
 The NIs could be important both in pathogenesis and in the selective vulnerability of each 
disease. However several reports show that this link between NIs and vulnerability may not be so 
straightforward. In HD, for instance, mouse models suggest dissociation between NIs and 
degeneration: transgenic mice expressing a fragment of mutant huntingtin have massive numbers of 
NIs, with relatively little neurodegeneration [162] whereas mice expressing full-length mutant 
huntingtin undergo significant striatal degeneration without many NIs [163]. Most importantly, recent 
results in the study of SCA1 transgenic mice strongly suggest that visible nuclear aggregates are not 
required for the initiation of pathogenesis [164]. 
 
We performed anti-ataxin-3 immunohistochemistry to analyse the subcellular localisation of 
ataxin-3. It is possible to observe (Figure 3.3) that ataxin-3 expression was increased in adult 
transgenic mouse brains, both in intensity and number of stained cells; in wild-type animals we 
observed less stained cells with diminished intensity. We could not find marked nuclear protein 
aggregation or inclusions, the sub localisation of ataxin-3 being predominantly perinuclear, but in 
this location it was possible to see aggregates (Figure 3.3). This sub-cellular localisation might 
correspond to an earlier phase of aggregation while later phases may be associated with nuclear 
aggregates. Formation of perinuclear aggregates in the presence of mutated ataxin-3 was very 
recently demonstrated in vitro: AT3Q72 transfected cells showed aggregates in the perinuclear zone 
at an earlier stage whereas after a longer post-transfection time the researchers could observe some 
nuclear aggregates [168]. 
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Neuropathology of transgenic mouse model unveils the presence of atrophic neurons… 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1. Neuropathology of CMVMJD94 mice. Comparative sections stained with H&E of wild-type and hemi 
CMVMJD94 mice thalami (A-D), dentate nuclei (E-H) and pontine nuclei (I-L) at 16 and 49 weeks of age. Transgenic 
CMVMJD94 mouse neurons in the thalamus and dentate nuclei were observed by H&E staining as scattered dark, 
shrunken cells with pyknotic nuclei and a basophilic cytoplasm (arrows) in comparison with normal cells observed in wild-
type animals. wt, wild-type; hemi, hemizygous. Scale bar 50 µm. 
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Figure 3.2. Astrogliosis in MJD transgenic mice brains. GFAP immunostaining of the substantia nigra (A-C) and the 
vestibular nuclei (D-F) at 12 months of age. Hemizygous and homozygous transgenic pCMVMJD94 mice (B, C, E, F) revealed an 
increase in immunostaining and the presence of reactive astrocytes in comparison with wild-type animals (A, D). Original 
magnification: × 200. The insets represent a high magnification (original magnification × 600) demonstrating the pycnotic neurons 
and the reactive astrocytes.   
 
… and astrogliosis in distinct areas of the CNS 
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Figure 3.3. Absence of large intranuclear inclusions in transgenic mice with motor impairment. 
Anti-ataxin-3 immunohistochemistry of wild-type and transgenic CMVMJD94 mice at late stages of the 
disease (49 weeks). Perinuclear localization of ataxin-3 was observed in CMVMJD94 transgenic mice. wt, 
wild-type; hemi, hemizygous. Scale bar 10 µm. 
 
Aggregated proteins with perinuclear localization in affected areas of MJD 
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3.4 Conclusion 
 
In this chapter we have described some brain pathological features found in our MJD 
transgenic mouse model.  
The presence of dark, shrunken cells with pyknotic or small, staining nuclei and eosinophillic 
cytoplasm observed after H&E staining, showed us that these cells may be dying or may be atrophic. 
In the next chapter we will focus on these hypotheses. We also showed increased reactive astrocytes 
by the immunostaining with GFAP.   
Another interesting observation is the presence of perinuclear aggregates and increased 
intensity of staining in transgenic mice cells when anti-ataxin-3 IHC is performed. This result shows 
that cytoplasmic aggregates may be important in the pathogenesis of MJD.  
All together, these results demonstrate that this MJD transgenic mice model has important 
features regarding pathology, and we think that this model is a great tool to study the early stages of 
MJD pathogenesis. 
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Chapter 4. Neurodegeneration in MJD mice: mapping and screening the cell death 
mechanisms 
 
4.1 Background 
 
Cell death is essential for embryonic development and maintenance of tissue homeostasis in 
multicellular organisms.  
It has long been evident that cell death is a carefully programmed process. Apoptosis is 
biochemically defined as a form of programmed cell death executed by a family of zymogenic 
proteases known as caspases that dismantle the cell in an orderly fashion by cleaving an array of 
intracellular substrates [169]. Activation of the caspase cascade in a chain reaction like fashion and 
subsequent cleavage of its downstream targets are therefore considered the biochemical hallmark of 
apoptotic cell death. 
Apoptosis occurs in a well choreographed sequence of morphological events [170]. The dying cell 
undergoes nuclear and cytoplasmic condensation with blebbing of the plasma membrane, and 
eventually breaks up into membrane-enclosed particles, termed apoptotic bodies, containing intact 
organelles, as well as portions of the nucleus leading to nuclear DNA breakdown into multiples of 
~200 bp oligonucleosomal size fragments. These apoptotic bodies are then rapidly recognized, 
ingested and degraded by professional phagocytes or neighbouring cells. Moreover, in some 
pathological conditions a combination of cell death by necrosis and apoptosis may occur. Besides 
these two types of cell death, other cell death mechanisms may be involved in polyQ diseases, such 
as autophagy (see review [173]). Apoptosis has been proposed as a possible mechanism for 
neuronal death in neurodegenerative diseases. However, there is no direct and convincing evidence 
of apoptosis in human brains of patients with these disorders, and the mechanisms of neuronal 
death in neurodegenerative diseases are still unknown. Apoptosis has been implicated in Alzheimer 
disease (AD). Neuropathologic studies of AD human brains show that the rate of apoptosis is 
increased 30- to 50-fold over that of age matched controls. Since apoptotic cells appeared to be 
cleared rapidly by the body, rapid clearance of apoptotic neurons in the AD-affected brain might lead 
to an underestimation of the total amount of apoptosis occurring in the disease. However, the 
significance of the increased apoptosis is unclear because the apoptosis could be one of many 
harmful processes occurring in the AD-affected brain. Some of the stimuli that induce apoptosis 
have also been implicated in the pathogenesis of Huntington’s disease (HD), and typical apoptotic 
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DNA fragmentation was shown to be increased in brains from post mortem HD patients [174]. 
Some reports demonstrate that apoptosis is a type of cell death involved in HD [175] and it 
correlates with disease progression [176]. The ability of the mutant Huntingtin protein to induce 
apoptosis suggests that apoptosis could play an important role in the pathology of Huntington 
disease. In other polyQ diseases, including MJD no clear evidence of cell death has been reported, 
therefore it is very important, in the context of the pathogenesis, to clarify this hypothesis.  
Are the atrophic neurons found in our MJD transgenic mouse model dying? 
In this study we used late-stage MJD transgenic mice with 86-100 weeks of age in order to 
screen and map the entire brain for neurodegeneration processes. We performed TUNEL assay to 
detect DNA fragmentation, which is the latest event in apoptosis; we used Fluoro Jade B, a 
fluorescent staining that can be used to detect necrotic-like cell death and we performed IHC anti-
active-caspase-3 to screen specifically for apoptotic cell death. We also performed western-blot to 
quantify the levels of active caspase-3 in mouse brains. 
 
4.2. Materials and methods 
 
DNA extraction and mouse genotyping 
As described in section 3.2. 
Animals  
The C57Bl/6 animals used in this study were all sacrificed, under anaesthesia (1mL 
Imalgène, 200 μL Domitor and 5.9 mL saline) by exsanguination and posterior perfusion using 100 
mL of saline solution per animal,. The tail and the brain were collected and the brain was emerged 
in a viscous solution (OCT) and frozen at -80ºC for posterior processing in the cryostat.  
Brain processing 
The slides were prepared in a freezing cryostat at a 10μm thickness. The slides were kept at 
-20ºC until use.  
TUNEL assay 
Frozen tissue sections (10μm) of mice aged 86 to 100 weeks  were fixed in 1% PFA for 30 
minutes and post-fixed in precooled Ethanol:Acetic acid (2:1) at -20ºC for 5 minutes. The sections 
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were washed in saline twice. Endogenous peroxidase was inactivated by immersing the tissue 
sections in 3% H2O2 in saline solution for 30 min and rinsing again with water and saline several 
times. In situ DNA end-labelling was accomplished using the Apoptag Peroxidase In situ Apoptosis 
Detection Kit (Chemicon) according to the manufacturer's instructions. 
In brief, sections were treated with 1× equilibration buffer, followed by application of terminal 
deoxynucleotidyl transferase enzyme solution and incubation in a humidified chamber at 37ºC for 1 
h. The slides were transferred to a stop buffer, rinsed in saline solution and covered with anti-
digoxigenin–peroxidase for 30 min at room temperature. After several washes in saline the color 
reaction was developed using freshly made substrate solution (0.05% 3,34-diaminobenzidine, 0.03% 
H2O2 in saline solution) and stopped in double distilled H2O. Nuclear counterstaining was 
performed with hematoxylin.  
 The slides were analyzed under a microscope (Olympus) using visible light. 
Immunohistochemistry anti-active-caspase-3 
For caspase-3 detection, frozen sections (10 μm) of brain mice with 86 to 100 weeks were 
fixed in 4% PFA and incubate with rabbit anti-active caspase-3 (R&D systems AF835, 1:250, diluted 
in saline solution) overnight at 4ºC. Detection of active-caspase-3 was assessed using LabVision kit 
according to the manufacturer’s instructions.   
The slides were analyzed under a microscope (Olympus - BX61) using visible light.  
Western-Blotting 
 Brain tissue (brainstem and cerebellum) of old animals (80 weeks) was 
homogenized in cold 0.1 M Tris-HCl, pH 7.5, 0.1 M EDTA, and a mixture of protease inhibitors 
(Complete; Roche). Protein concentration was determined using the Bradford assay (Biorad). 
Samples were sonicated for 10 sec, heated for 3 min at 100°C, and microfuged for 10 sec before 
loading. Seventy five micrograms of total protein was loaded into SDS-Page gels and then transferred 
to nitrocellulose membranes. After incubation with the primary antibodies: rabbit anti-active caspase-
3, (1:200, R&D systems AF835) rabbit anti-calbindin (1:1000, Millipore) and mouse anti-alpha-
tubulin (1:100, DSHB) the secondary antibodies were incubated at the following dilutions: anti-rabbit 
(1:500, Pierce) and anti-mouse (1:500, Pierce). Antibody affinity was detected by 
chemiluminescence (ECL kit, Santa Cruz). Band quantification was performed using ImageJ 
according to the software manufacturer’s instructions using alpha-tubulin as the loading control.   
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Fluoro Jade B  
Frozen tissue sections (10μm) of mice with 86 to 100 weeks first immersed in a solution 
containing 1% sodium hydroxide in 80% alcohol (20 mL of 5% NaOH added to 80 mL absolute 
alcohol) for 5 minutes. This was followed by 2 minutes in 70% alcohol and 2 minutes in distilled 
water. This was followed by 2 minutes in 70% ethanol an 2 minutes in distilled water. The slides 
were then transferred to a solution of 0.06% of potassium permanganate for 10 minutes in a shaker 
table, followed by two washes in distilled water. The slides were emerged in staining solution, 
0,001% of Fluoro-Jade B (Chemicon) solution for 20 minutes and then rinsed three times in distilled 
water one minute each.  
The slides were analyzed under a microscope (Olympus) using FITC filter. 
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4.3 Results and discussion 
Transgenic and wild-type mice show the same pattern of TUNEL staining 
The TUNEL assay is an in situ method to detect cells with DNA strand breaks. The Terminal 
Deoxynucleotide Transferase dUTP Nick End Label (TUNEL) allows detection of free 3’-OH termini 
present in the DNA of apoptotic cell by enzymatic labeling. DNA fragmentation is a late event in 
apoptosis and there are some data suggesting that DNA fragmentation occurs not only by apoptosis 
but also in necrotic cells [177-178] and there is evidence that this may be the case for neurons 
[179-180]. 
In this work we investigate the apoptotic cell death using the TUNEL assay. MJD transgenic 
mice with 86-100 weeks of age were used in this study. We have screened the entire brain in order 
to obtain the maximum of information. Generally, the TUNEL assay did not reveal differences in its 
pattern between wild-type and transgenic animals (Figure 4.1), and the staining observed was 
probably related to the age of the animals and not with pathology itself. Interestingly, in the areas 
that we have found pathological features - dentate and pontine nuclei, substantia nigra, vestibular 
nuclei and thalamus – (see chapter 3) we have also found no TUNEL positive cells, suggesting that 
apoptosis may not be the type of cell death occurring in these cells. 
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Figure 4.1. TUNEL assay of non-transgenic, hemi and homozygous MJD transgenic mice at 86-100 
weeks of age in subventricular zone, cerebellum and hippocampus. Microscopic sections were cut at 10 μM 
and were subjected to TUNEL assay. (A-I) Wild-type (wt), hemizygous (hemiA) and homozygous (homoA) mice 
from lineage A show few TUNEL positive cells (arrows) in the brain areas shown in this panel but the same is 
true for the entire brain. N=4 (J) mammary glands of female rats after weaning as a TUNEL positive control. (K) 
TUNEL assay negative control.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter  4. Cell death mechanisms 
47 
Caspase-3 activation is similar between normal animals and MJD animals 
The apoptotic cell death pathway is executed by caspases, a family of aspartyl-specific 
cysteine proteases [181-182]. Caspase-3 and 9 are the main executioner caspases in the brain and 
their activation has been described in HD mouse models and in HD human brains [183-184]. 
In order to further exclude apoptosis as a cell death type occurring in our MJD transgenic 
mice, we performed immunohistochemistry anti-active caspase-3 in the same animals and in serial 
sections of the entire brain. Our results, in accordance with those of the TUNEL assay, showed that 
caspase-3 is not activated in wild type nor in transgenic mice (Figure 4.2) both in spared areas and 
in those where we found pathology. 
 We also performed quantitative anti-active caspase-3 Western-blot in the cerebellum 
and brainstem of 80 weeks old animals, to confirm our IHC result, and we did not see any 
significant differences in these two areas between wild-type and transgenic animals (figure 4.3). 
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Figure 4.2. IHC anti-active caspase-3 of non-transgenic, hemi and homozygous MJD transgenic mice at 86-100 weeks 
of age in subventricular zone, cerebellum and hippocampus. Microscopic sections were cut at 10 μM and were subjected to 
IHC. (A-I) Wild-type (wt), hemizygous (hemiA) and homozygous (homoA) mice from lineage A show no active caspase-3 cells in 
the brain areas shown in this panel but the same is true for the entire brain. N=4 (J) mammary glands of female rats after 
weaning as a caspase-3 positive control. (K) IHC negative control (without primary antibody).  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3. Western-blot anti-caspase-3 of non-transgenic and hemizygous MJD transgenic mice at 80 weeks of 
age in cerebellum and brainstem. At the protein level there is no differences between wild type and transgenic mice for 
caspase-3. t test analysis, p<0.05. N=4 
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Necrosis is not increased in MJD transgenic mice 
Our results suggest that apoptosis is not occurring in the regions containing atrophic 
neurons that we observed in chapter 3. However necrosis has also been described to be implicated 
in HD [175] and other neurodegenerative disorders, and it could be occurring also in MJD. 
Fluoro-Jade is an anionic fluorochrome capable of selectively staining degenerating neurons 
in brain slices. The histochemical application of Fluoro-Jade results in a simple, sensitive and 
reliable method for staining degenerating neurons and their processes [185].  
Once again, we used 80 weeks old animals and we screened the entire brain performing 
Fluoro-Jade B staining. Our results show that there is no difference in this staining between wild-type 
and transgenic mice (Figure 4.4) and again we did not found correlation with pathological brain 
areas. In contrast a recent report using a model of MJD in rat, generated using lentiviral vectors, 
showed Fluoro-Jade positive cells in the striatum, suggesting neuropathology in this “spared” area of 
the disease [152]. The use of lentiviral vectors as an alternative way to obtain a disease model, lead 
in this case to a localized strong overexpression of the mutant protein, possibly promoting 
neurodegeneration in these usually spared brain regions. 
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Figure 4.4. Fluoro-Jade B staining of non-transgenic, hemi and homozygous MJD transgenic mice at 
86-100 weeks of age in cerebellum and hippocampus. Microscopic sections were cut at 10 μM and were 
subjected to this staining.  Wild-type (wt), hemizygous (hemiA) and homozygous (homoA) mice from lineage A 
show no differences in FJB pattern. N=4 
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Figure 4.5. Western-blot anti-calbindin of non-transgenic and hemizygous MJD transgenic mice at 80 weeks of 
age in cerebellum and brainstem. At the protein level there are no difference between wild type and transgenic mice for 
calbindin. t test analysis, p<0.05. N=4 
All together, our results suggest that another cell death type might be happening or instead, 
that these are dysfunctional, rather than dying, neurons.  
Transcriptional deregulation has been proposed in the ataxin-3-Q79 transgenic mouse model 
of MJD [151], where the authors did not find neuronal loss in the cerebellum, as well as in other 
mouse models of MJD [149-150]. In a microarray study of the ataxin-3-Q79 mouse model, the 
expression of several genes was found to be altered, including the downregulation of genes involved 
in the intracellular Ca2+ signalling [151]. The same was described for other SCAs and for DRPLA 
[186-189].  
Glutamate-mediated 'excitotoxicity', a term coined to describe an excessive release of 
glutamate, and a subsequent over-activation of excitatory amino acid (NMDA, AMPA, and kainite) 
receptors may occur first via a rapid influx of Ca2+ through voltage-gated calcium channels, caused by 
the depolarization of the membrane after AMPA receptor activation (and through Ca2+ permeable 
AMPA receptors themselves), and second, via a delayed release of Ca2+ from intracellular stores. 
Excessive Ca2+ influx can detrimentally alter dendritic spine morphology via interactions with the 
neuronal cytoskeleton, and thus can perturb normal synaptic function. Calcium-binding proteins, 
such as calbindin-D28K may help to prevent glutamate from exerting deleterious effects [190].  
 In order to evaluate the relevance of this pathway in MJD, we performed a western-blot 
detection of calbindin, a calcium-binding protein present in dendrites, soma, and axons of Purkinje 
cells, using 80 weeks old transgenic mice. Both in cerebellum and brainstem we could not observe 
any statistical difference in the intensity of staining between wild type and transgenic animals (Figure 
4.5). Until now we only tested this protein, although several other molecules should be tested in 
order to obtain an answer, such as calcineurin B and myosin Va.  
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4.4 Conclusion   
This chapter represents a novel study, since the analysis of different pathways of cell death 
using different has not been described in the literature, in MJD models or human brains.  
We have shown that apoptosis and necrosis are two cell death processes that are not 
happening in our mouse model; it is still possible that autophagy, another way for cells to dye, may 
be behind this neurodegeneration process [112-114, 191]. Alternatively, processes such as synaptic 
dismantling may be involved. 
Another possibility could be the abnormal functioning of neurons without cell death. So far 
we have not detected any neuronal death, the observed pathological features mentioned before, may 
support the hypothesis of dysfunctional neurons. However, we also need to perform a rigorous 
stereological analysis and to study autophagy in order to exclude the neuronal death hypothesis. 
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Chapter 5. CAG repeat instability in a MJD transgenic mouse model 
  
5.1  Background  
A triplet repeat disease, including MJD, can be defined as a disease caused by the unstable 
expansion of a triplet repeat tract [192].  
In the first description of the MJD gene in 1994, screening for CAG repeat expansions in 12 
Japanese SCA patients with clinical signs of MJD revealed a repeat expansion from 68 to 79 CAGs 
in 11 of the patients whereas 72 healthy Japanese controls harboured between 13 and 36 repeats 
[7]. This early evidence showed that in mutant as in normal alleles, these triplet repeats are quite 
polymorphic.  
A large number of genetic studies over the last 15 years finally defined the normal range of 
CAG repeats in the MJD gene fewer than 44 and the expanded repeat size of more than 45 [193], 
86 being the largest expanded repeat described [156]. Studies also indicated that the expanded 
CAG repeat is widely unstable during paternal transmission [194], showed evidence for somatic 
mosaicism of the expanded allele [31], and revealed that, besides the expanded CAG repeat length, 
additional genetic factors exist manifesting the age at onset of MJD [194-195]. 
Germline mutations are involved in triplet repeat instability. Progressively larger expanded 
CAG repeat sizes are correlated with the earlier age at onset in successive generations, which is 
known as anticipation. Intergenerational instability in MJD is more prominent in paternal than in 
maternal transmission [35, 194]. Processes that are specific to sperm or oocyte development may 
be involved in these biases [44, 196]. Female cell production occurs before birth and requires a 
limited number of cell divisions [197] while the majority of male germline production occurs after 
birth with regular spermatogonial stem cells cycles [198]. However, as other highly proliferative 
tissues show lower levels of instability than sperm, there must be other factors, rather than the rate 
of cell division, contributing to repeat instability. Somatic mosaicism of the repeat sizes in CAG 
repeat disorders describes that different cells of the same individual carry different repeat sizes. 
Somatic instability has been described for MJD in different brain areas [31] with smaller expanded 
repeat sizes in the cerebellar cortex than in other brain regions such as the frontal cortex [199]. 
Repeat length heterogeneity has been observed both in proliferating and in non-proliferating tissues 
[37-38, 200-201], suggesting that other factors, besides proliferation status, are contributing to the 
extent of somatic mosaicism. 
Chapter 5. CAG repeat instability 
56 
A logical question that arises then is whether this somatic mosaicism of repeat length has 
any impact in the specificity of cell death: does polyglutamine load contribute to cell-specific 
vulnerability in these disorders? 
In HD, this question was addressed in humans [38] and in a mouse model; indeed this 
seemed to be the case, since the CAG tract was more expanded in the striatum, the most affected 
area in this disease [202]. This simplistic correlation was not, however, confirmed in other 
polyglutamine diseases. 
  
 In this chapter we tried to answer the following questions: does our transgenic 
mouse model display intergerational instability? And somatic mosaicism? Is mosaicism age-
dependent? Is there a correlation between the degree of mosaicism and pathological involvement? 
 In order to answer to the first question we used DNA from tail tissue of male and 
female transgenic C57Bl/6 and FVB/N mice and analysed them and their progeny. We used two 
different genetic backgrounds in order to see if this instability was background-dependent. To 
investigate the second and third questions we used DNA from several brain regions of males 
C57Bl/6 transgenic mice with 5, 24, 60 and 72 weeks of age. 
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5.2 Materials and methods 
5.2.1 Intergerational instability 
DNA extraction and genotyping 
As described in section 3.2. 
Molecular analysis of the CAG repeat 
The (CAG)2CAAAAGCAGCAA(CAG)n repeat tract and a 75 bp flanking region of the ATXN3 
gene was amplified by PCR using the primers MJD25a (5’GGC TGG CCT TTC ACA TGG AT 3’) and 
MJDcDNA (5’CGG AAG AGA CGA GAA GCC TAC 3’). 
 
Relative CAG variation across generations was analysed by PCR amplification of DNA 
extracted from tail biopsies with the primers described above, using incorporation of [203] dATP, 
and separation in a denaturating polyacrylamide gel as described [204]. For determination of the 
major allele size the films were visualized with AlphaImager 2200 (AlphaInnotech, San Leandro, CA, 
USA) and bands were analyzed densitometrically with the corresponding AlphaEase software to 
detect the highest peak. CAG variation was determined by comparison with the migration of the 
highest peak band from PCR products generated from parental and progenitor DNAs. 
 
For analysis of the CAG repeat, namely the determination of the CAG repeat number and the 
analysis of the somatic mosaicism in transgenic mice, DNA was extracted from several brain regions 
(motor and cerebellar cortex, deep cerebellar nuclei, hippocampus, hypothalamus, amygdala, 
striatum, substantia nigra and pontine nuclei) and also from tail tissue and amplified by PCR; primer 
MJDcDNA was fluorescently labelled with 6-FAM and products were displayed on an ABI 310 
automated DNA sequencer (Applied Biosystems). 
 
The analysis of the degree of mosaicism in the different tissues of mutant mice was 
performed by calculations the mosaicism index (MI) as described by [205-206]. The number of 
bands with peak areas of at least 10% that of the major band were counted and their surfaces 
summed. MI was defined as the ration between this sum and the area of the major size band. In 
order to avoid inclusion of PCR artifacts, only bands larger than the major bands were taken into 
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account. The CAG tract length of the highest peak was determined using an equation from the 
calibration curve obtained with cloned alleles containing known numbers of CAG repeats. 
 
Statistical analysis  
Continuous variables with normal distribution (K-S test p>0.05) were analyzed with the 
Student t-test and ANOVA. All statistical analyses were performed using SPSS 16.0 and a critical 
value for significance of p< 0.05 was used throughout the study. 
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5.3 Results and discussion 
Parental gender and genetic background-dependent pattern of CAG intergenerational 
instability 
To investigate whether, as human patients, MJD transgenic mice displayed intergenerational 
instability, we determined the CAG repeat tract length in both maternal and paternal meioses of 
animals from lineage A. This analysis was performed in lineage A because it carries only two copies 
of the transgene, making this analysis of length variation easier. In order to identify genetic effects 
upon repeat instability, we used hemizygous male and female transgenic from lineage A in two 
different genetic backgrounds, C57Bl/6 and FVB/N.  
Studies regarding MJD patients showed no significant difference in frequency of 
contractions, stable inheritance or expansions between male or female meioses, but an increased 
variability was found in the CAG repeat tract length when paternally transmitted [24]. We observed 
that CAG repeat length in transgenic mice varied through generations in more than 50% of the 
transmissions: the expanded allele had the tendency to expand when transmitted through the male 
progenitor and to contract when transmitted from the female progenitor (Figure 5.1 A).  This gender 
bias has also been demonstrated in other polyQ diseases, such as HD [207]. The genetic 
background seemed to affect the pattern of instability and, this gender observation reached 
statistical significance in the C57Bl/6 background (p<0,05) (Figure 5.1 B). Distribution of CAG 
length variation in the two strains suggests that background-specific modifier loci might affect the 
degree of intergerational instability. 
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Figure 5.1. Intergenerational instability of the expanded CAG repeat in MJD transgenic mice.  
(A) Polyacrilamide gels showing the variation of the CAG repeat tract length of male and 
female transgenic mice progenitors and their respective descendants. (B) Differential pattern 
of CAG repeat variation in MJD transgenic mice throughout male and female meioses in the 
FVB/N and C57Bl/6 genetic background. 
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Progression of CAG repeat variability in somatic tissues of MJD mice during aging 
The analysis of the CAG repeat in different tissues of transgenic mice revealed the existence 
of somatic mosaicism of the expanded allele: several bands, larger and smaller than the major band 
were observed; however, to avoid confounding by polymerase slippage and incomplete amplification 
effects, only the larger bands were considered in the analysis as proposed by Cancel and collegues 
[205]. 
When we planned this experiment, we decided to analyse the degree of instability in different 
neuronal areas and also in peripheral tissues. As show in figure 5.2, somatic mosaicism was 
present in all tissues analysed, except heart. In some of the areas affected in MJD, such as the 
pontine nuclei and substantia nigra, the MI was higher, however this was also observed in areas 
thought to be spared in the disease, such as the striatum and the liver. In the liver this probably 
happens due to the well-known capacity of this organ to regenerate and proliferate [208]. Regarding 
other non neural tissues in MJD patients, the muscle exhibited a lesser degree of CAG instability, 
while the liver, kidney and colon displayed a greater diversity of extra bands and more extended 
major band compared to CNS [211]. 
Each CNS tissue is predominantly composed of post-mitotic neuronal cells and glial cells 
that can continue to divide in the postnatal period. The proportion of these two main cell types 
differs among the tissue analyzed. This fact may explain the different pattern of MI observed the 
neuronal tissues that we have analysed. Given that in HD, DRPLA, SCA1 and MJD patients the 
cerebellar cortex has the smallest repeat size and least mosaicism of all CNS regions studied [37-
38, 209], and because the ratio of neuronal to glial cells in cerebellar cortex is higher than 
elsewhere, it was suggested that the main source of expanded repeat instability in the CNS would be 
the glia that continue dividing, whereas neurons are postmitotic [37]. This hypothesis is supported 
by a study in DRPLA post mortem brain specimens [210], where a wider range of repeat sizes was 
observed in older individuals. It was postulated that the continuous mitotic division of the glial cells 
throughout life leads to this increased somatic mosaicism. Besides proliferative capacity, other 
mechanism may be behind this instability, such as the involvement of the mismatch repair system 
described very recently in HD [207].  
 Our results suggests that the somatic mosaicism is a relevant feature of our MJD 
transgenic model, mimicking what is happening in MJD patients, and indeed this instability is an 
age-dependent process (Figure 5.2). Generally, in all tissues analysed, age seems to be an important 
factor, since we demonstrate that at 5 weeks the mosaicism is lower and increases with age. This 
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was also observed in other triplet diseases such as Myotonic dystrophy and SCA1 [212-213]. 
However, somatic mosaicism seems to be the result of differences in the pattern of development 
and/or cell composition of each structure in CNS, and not to be directly correlated with the specific 
pattern of cell death. Thus, these results do not completely exclude the possibility that glial cells 
might be the main contributors to the somatic mosaicism of expanded repeat size: more detailed 
studies, using microdissection and single-cell PCR, would be needed in order to improve our 
understanding of the origin and biological relevance of somatic mosaicism in this disease. 
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Figure 5.2. Age-dependent somatic mosaicism of the expanded CAG repeat in neuronal and non-
neuronal tissues MJD transgenic mice. (A) Representative genescan tract diagrams of the CAG repeat pattern 
of neuronal and non-neuronal tissues from MJD transgenic mice at different ages. (B) Differential pattern of 
mosaicism index increase through aging for pCMVMJD94 hemizygous mice. Mean (at least three independent 
samples) ± SE, * p<0,05 
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5.4 Conclusion 
In this chapter we demonstrate that the human CAG mutation in our MJD transgenic mouse 
model is not stable, but a dynamic mutation. Our model displays intergerational instability which is 
genetic background specific and is dependent on gender. In order to study the intergerational 
instability in our mouse model, we assess the CAG repeat tract length both in paternal and maternal 
meioses. The amplification of the transgene by PCR, showed a pattern of bands similar to those 
found in heterozygous human patients [31]. 
We also found differences in the CAG instability behaviour between male and female 
transmissions, and the mild instability found in our model was in agreement with that described in 
MJD patients [24].  
We observed that different tissues exhibited different patterns of MI during aging. The cells 
from the liver, pontine nuclei, substantia nigra and striatum displayed the highest MI increases and 
the cells from the cerebellar cortex and muscle the lowest MI increases trough age.  
We have found pathological involvement in the pontine nuclei and the substantia nigra but 
we did not observe anomalies in the striatum which led us to conclude that the specific increase of 
somatic mosaicism in these areas was not clearly correlated with specific cell vulnerability in this 
mouse model. Age has been described as a CAG repeat instability modifier [214-216], as so our 
results are in accordance with those obtained in other animal models of different polyQ diseases. 
Although a correlation between somatic mosaicism and pathology was not clear, our results 
concerning the CAG variation pattern in transgenic mice from lineage A, revealed that this mouse 
model can be useful for the study of the molecular basis of the CAG repeat instability, as well as of 
MJD pathogenesis. 
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Chapter 6. General Discussion 
 
In the last years, a lot has been done in the attempt to understand the pathogenic 
mechanism of polyQ diseases, including MJD. The common features between different polyQ 
diseases, make researchers believe that probably there a common mechanism underlying all these 
disorders since each of the expanded CAG repeats encodes polyglutamine and the pathogenic 
threshold for disease is roughly the same, at around 40 copies of the repeat in most of the different 
subtypes.  
It is assumed that the common toxic gain-of- function mechanisms for the polyglutamine-
containing protein depend on aggregation and deposition of misfolded proteins leading to neuronal 
dysfunction and eventually cell death [217]. 
Enigmatically, despite the fact that the majority of the proteins associated with 
spinocerebellar neurodegenerative disease are expressed systemically, the resulting cytotoxicity 
appears restricted to a few neuronal subtypes of the CNS [19]. Selective cellular conditions and 
specific protein–protein interactions might confer local insolubility conditions, leading to 
oligomerization and fibrillization in vulnerable neurons.  
 Despite well-described clinical and pathological phenotypes, the molecular and 
cellular events that underlie neurodegeneration in these disorders are still poorly understood. 
Compelling evidence points to major aetiological roles for interference with transcriptional regulation, 
protein aggregation and clearance, the ubiquitin-proteasome system and alterations of calcium 
homeostasis in the neuronal loss observed during the neurodegenerative process. But novel 
molecular routes that might be disrupted during disease progression are also being identified. These 
pathways could act independently or, more likely, interact and enhance each other, triggering the 
accumulation of cellular damage that eventually leads to dysfunction and, ultimately, the demise of 
neurons through a series of multiple events [2]. This suggests that simultaneous targeting of several 
pathways might be therapeutically necessary to prevent neurodegeneration and preserve neuronal 
function. Understanding how dysregulation of these pathways mediates disease progression is 
leading to the first attempts of obtaining effective therapeutic strategies in vivo, which may prove 
beneficial in the treatment of polyQ diseases. 
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Figure 6.1. Molecular mechanisms of neurodegeneration in spinocerebellar ataxias. 1, aggregation; 2, apoptosis; 3, 
autophagy; 4, Ca2+ homeostasis alterations; 5, disruption of axonal transport and vesicle trafficking; 6, excitotoxicity; 7, 
interference with gene transcription; 8, mitochondrial impairment; 9, oxidative stress; 10, alterations of proteasome 
degradation; 11, synaptic dysfunction; 12, unfolded protein response (UPR); 13, potassium channel dysfunction; Ca2+, 
calcium ions; ER, endoplasmic reticulum; Glu, glutamate; K+, potassium ions; Na+, sodium ions; Q, glutamine; Ub, 
ubiquitin. Adapted from [2] 
 
 
 
 
 
 
 
 
 
As shown in figure 6.1, several pathways may be involved in polyQ pathogenesis and may 
act together rather than individually. In our work we explored some of these pathways (orange 
circles) however we still need to check other pathways that can lead to MJD pathogenesis (yellow 
squares). We could observe atrophic neurons and perinuclear inclusions in MJD transgenic mouse 
brains, as described in chapter 3, and we screened for different types of cell death in the entire 
brain of these mice (chapter 4). We could conclude that the types of cell death analysed are not 
happening in our model; we will next address autophagy, and eventually other pathways must be 
studied in other to have more clues about this crucial topic. Evidences of autophagic cell death have 
been proposed in several neurodegenerative diseases [112-114, 191]. Rapamycin, an inducer of 
autophagy, reduces the aggregation of expanded polyQ in transfected cells [218], protects against 
neurodegeneration in a fly model of Huntington disease, and improves performance on behavioural 
tests and decreases aggregate formation in a mouse model of Huntington disease [219]. Autophagy 
could be the next step in this study and may be a good target for therapeutically strategies [35]. 
 
Another common feature of polyQ diseases is the dynamics of the trinucleotide repeats. 
Tissue-specific instability occurs during human [38, 220-221] or animal [45, 202] development in 
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trinucleotide repeats disorders. Somatic variation in repeat tract length is observed in the brains of 
individuals affected by HD [38], Machado-Joseph disease, SCA1 [209] and spinobulbar muscular 
atrophy (SBMA) [222]. Intergerational instability is present is this type of disorders and is 
responsible for the onset of the disease and when transmitted by paternal meiosis tend to aggravate 
the symptoms on the offspring [35, 194]. Another aspect of the dynamics of the mutation is seen in 
somatic tissues and this fact could be related to the vulnerability of the areas affected in the polyQ 
diseases. To address this question in our model we performed an extensive study, using several 
neuronal and non-neuronal tissues from transgenic mice during age, at 5, 24, 60 and 72 weeks of 
age. Although in some brain areas such as the pontine nuclei and the substantia nigra there was a 
tendency to an increased somatic instability, we could not find a clear correlation between 
vulnerable areas in the disease and a higher mosaicism index. 
 Finally, although this work is focused on Machado-Joseph disease, we believe that 
some of our results may be transposed to other polyglutamine disorders. 
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Chapter 7. Main conclusions of the work 
 
- Pathological analysis of CMVMJD94Q transgenic mouse brains showed atrophic neurons 
and increased astrogliosis in regions such as substantia nigra and vestibular nuclei.   
- The presence of perinuclear aggregates, but not nuclear inclusions, was detected in 
CMVMJD94Q transgenic mouse brains by reactivity with ataxin-3; 
- No differences were observed in TUNEL positive cells, caspase-3 positive cells, Fluoro-Jade 
B staining and calbindin protein levels between wild-type and CMVMJD94Q transgenic mice; 
- This model shows a generally homogeneous pattern of somatic mosaicism in several CNS 
and non-neuronal tissues, showing a tendency towards higher instability in some disease 
affected areas of such as the pontine nuclei and the substantia nigra but also in disease 
spared areas such as the striatum, and non-affected organs such as the liver. 
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Chapter 8. Future perspectives 
 
 
 
The CMVMJD94Q transgenic mouse model shows an important overlap with 
genetic and clinical features of MJD, namely intergenerational instability of the expanded 
CAG repeat, pathological hallmarks of the disease (atrophic neurons and astrogliosis) and 
motor coordination impairment.  
 
  This work opened some questions that we want to address soon and gave us the 
opportunity to begin other studies such as the development of therapeutic strategies using 
this mouse as a model, and pathology findings as biomarkers for assessment of 
effectiveness of therapies.  
 
  We want to analyse the neuronal dysfunction further, studying markers of some 
pathways that may be involved on this process, such as markers of calcium signalling, 
GABAergic and glutamatergic transmission (VGLUT2, IP3-RI), and autophagy 
(autophagosomes, Bax, Bcl-2), among others. 
 
  We will also focus our attention and energy into studying the effect of a selection of 
drugs that target different pathways: (1) transcription deregulation; (2) oxidative stress; (3) 
autophagy.  
We will test the effects of compounds targeting the potential pathogenic pathways: 
transcription deregulation (phenylbutyrate, SAHA and resveratrol), oxidative stress 
(creatine) and autophagy (lithium and rapamicyn) in this mouse model for MJD. The 
compounds that improve significantly the motor phenotype and show to be non toxic, could 
be interesting candidates for future clinical trials in MJD patients and can also contribute 
for the knowledge of the pathogenic mechanism(s) of this disease. 
 
 
 
 
 
  
 
 
 
  
 
 
 
Chapter 9. References 
 
Chapter 9. References 
81 
Chapter 9. References 
 
 
1. Paulson, H.L., Protein fate in neurodegenerative proteinopathies: polyglutamine diseases 
join the (mis)fold. Am J Hum Genet, 1999. 64(2): p. 339-45. 
2. Duenas, A.M., R. Goold, and P. Giunti, Molecular pathogenesis of spinocerebellar ataxias. 
Brain, 2006. 129(Pt 6): p. 1357-70. 
3. Ross, C.A., When more is less: pathogenesis of glutamine repeat neurodegenerative 
diseases. Neuron, 1995. 15(3): p. 493-6. 
4. Zoghbi, H.Y. and H.T. Orr, Glutamine repeats and neurodegeneration. Annu Rev Neurosci, 
2000. 23: p. 217-47. 
5. Gusella, J.F. and M.E. MacDonald, Molecular genetics: unmasking polyglutamine triggers in 
neurodegenerative disease. Nat Rev Neurosci, 2000. 1(2): p. 109-15. 
6. Margolis, R.L. and C.A. Ross, Expansion explosion: new clues to the pathogenesis of repeat 
expansion neurodegenerative diseases. Trends Mol Med, 2001. 7(11): p. 479-82. 
7. Kawaguchi, Y., et al., CAG expansions in a novel gene for Machado-Joseph disease at 
chromosome 14q32.1. Nat Genet, 1994. 8(3): p. 221-8. 
8. A novel gene containing a trinucleotide repeat that is expanded and unstable on 
Huntington's disease chromosomes. The Huntington's Disease Collaborative Research 
Group. Cell, 1993. 72(6): p. 971-83. 
9. La Spada, A.R., et al., Androgen receptor gene mutations in X-linked spinal and bulbar 
muscular atrophy. Nature, 1991. 352(6330): p. 77-9. 
10. Nagafuchi, S., et al., Dentatorubral and pallidoluysian atrophy expansion of an unstable CAG 
trinucleotide on chromosome 12p. Nat Genet, 1994. 6(1): p. 14-8. 
11. Nagafuchi, S., et al., Structure and expression of the gene responsible for the triplet repeat 
disorder, dentatorubral and pallidoluysian atrophy (DRPLA). Nat Genet, 1994. 8(2): p. 177-
82. 
12. Tallaksen-Greene, S.J., et al., Hprt(CAG)146 mice: age of onset of behavioral abnormalities, 
time course of neuronal intranuclear inclusion accumulation, neurotransmitter marker 
alterations, mitochondrial function markers, and susceptibility to 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine. J Comp Neurol, 2003. 465(2): p. 205-19. 
13. Green, H., Human genetic diseases due to codon reiteration: relationship to an evolutionary 
mechanism. Cell, 1993. 74(6): p. 955-6. 
Chapter 9. References 
82 
14. Perutz, M.F., et al., Glutamine repeats as polar zippers: their possible role in inherited 
neurodegenerative diseases. Proc Natl Acad Sci U S A, 1994. 91(12): p. 5355-8. 
15. Ikeda, H., et al., Expanded polyglutamine in the Machado-Joseph disease protein induces 
cell death in vitro and in vivo. Nat Genet, 1996. 13(2): p. 196-202. 
16. Mangiarini, L., et al., Exon 1 of the HD gene with an expanded CAG repeat is sufficient to 
cause a progressive neurological phenotype in transgenic mice. Cell, 1996. 87(3): p. 493-
506. 
17. Walsh, R., et al., The roles of proteolysis and nuclear localisation in the toxicity of the 
polyglutamine diseases. A review. Neurotox Res, 2005. 7(1-2): p. 43-57. 
18. Ross, C.A., Intranuclear neuronal inclusions: a common pathogenic mechanism for 
glutamine-repeat neurodegenerative diseases? Neuron, 1997. 19(6): p. 1147-50. 
19. Orr, H.T. and H.Y. Zoghbi, Trinucleotide repeat disorders. Annu Rev Neurosci, 2007. 30: p. 
575-621. 
20. Kordasiewicz, H.B. and C.M. Gomez, Molecular pathogenesis of spinocerebellar ataxia type 
6. Neurotherapeutics, 2007. 4(2): p. 285-94. 
21. Coutinho, P., A. Guimaraes, and F. Scaravilli, The pathology of Machado-Joseph disease. 
Report of a possible homozygous case. Acta Neuropathol, 1982. 58(1): p. 48-54. 
22. Sinden, R.R., Biological implications of the DNA structures associated with disease-causing 
triplet repeats. Am J Hum Genet, 1999. 64(2): p. 346-53. 
23. Zoghbi, H.Y. and H.T. Orr, Polyglutamine diseases: protein cleavage and aggregation. Curr 
Opin Neurobiol, 1999. 9(5): p. 566-70. 
24. Maciel, P., et al., Correlation between CAG repeat length and clinical features in Machado-
Joseph disease. Am J Hum Genet, 1995. 57(1): p. 54-61. 
25. Rubinsztein, D.C., et al., Phenotypic characterization of individuals with 30-40 CAG repeats 
in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently 
normal elderly individuals with 36-39 repeats. Am J Hum Genet, 1996. 59(1): p. 16-22. 
26. Paulson, H.L. and K.H. Fischbeck, Trinucleotide repeats in neurogenetic disorders. Annu 
Rev Neurosci, 1996. 19: p. 79-107. 
27. Andresen, J.M., et al., The relationship between CAG repeat length and age of onset differs 
for Huntington's disease patients with juvenile onset or adult onset. Ann Hum Genet, 2007. 
71(Pt 3): p. 295-301. 
Chapter 9. References 
83 
28. Pianese, L., et al., The effect of parental gender on the GAA dynamic mutation in the FRDA 
gene. Am J Hum Genet, 1997. 60(2): p. 460-3. 
29. Ravina, B., et al., The relationship between CAG repeat length and clinical progression in 
Huntington's disease. Mov Disord, 2008. 23(9): p. 1223-7. 
30. Igarashi, S., et al., Intergenerational instability of the CAG repeat of the gene for Machado-
Joseph disease (MJD1) is affected by the genotype of the normal chromosome: implications 
for the molecular mechanisms of the instability of the CAG repeat. Hum Mol Genet, 1996. 
5(7): p. 923-32. 
31. Maciel, P., et al., Mosaicism of the CAG repeat in CNS tissue in relation to age at death in 
spinocerebellar ataxia type 1 and Machado-Joseph disease patients. Am J Hum Genet, 
1997. 60(4): p. 993-6. 
32. Chung, M.Y., et al., Evidence for a mechanism predisposing to intergenerational CAG repeat 
instability in spinocerebellar ataxia type I. Nat Genet, 1993. 5(3): p. 254-8. 
33. La Spada, A.R., et al., Meiotic stability and genotype-phenotype correlation of the 
trinucleotide repeat in X-linked spinal and bulbar muscular atrophy. Nat Genet, 1992. 2(4): 
p. 301-4. 
34. Duyao, M., et al., Trinucleotide repeat length instability and age of onset in Huntington's 
disease. Nat Genet, 1993. 4(4): p. 387-92. 
35. Maruyama, H., et al., Molecular features of the CAG repeats and clinical manifestation of 
Machado-Joseph disease. Hum Mol Genet, 1995. 4(5): p. 807-12. 
36. Lin, Y., L. Hubert, Jr., and J.H. Wilson, Transcription destabilizes triplet repeats. Mol 
Carcinog, 2009. 48(4): p. 350-61. 
37. Chong, S.S., et al., Gametic and somatic tissue-specific heterogeneity of the expanded SCA1 
CAG repeat in spinocerebellar ataxia type 1. Nat Genet, 1995. 10(3): p. 344-50. 
38. Telenius, H., et al., Somatic and gonadal mosaicism of the Huntington disease gene CAG 
repeat in brain and sperm. Nat Genet, 1994. 6(4): p. 409-14. 
39. Ito, Y., F. Tanaka, and G. Sobue, [Somatic mosaicism of CAG repeats size in the nervous 
system of dentatorubral-pallidoluysian atrophy (DRPLA)]. Nippon Rinsho, 1999. 57(4): p. 
850-5. 
40. Nakamura, M., et al., Exonic trinucleotide repeats and expression of androgen receptor gene 
in spinal cord from X-linked spinal and bulbar muscular atrophy. J Neurol Sci, 1994. 122(1): 
p. 74-9. 
Chapter 9. References 
84 
41. Eichler, E.E., et al., Length of uninterrupted CGG repeats determines instability in the FMR1 
gene. Nat Genet, 1994. 8(1): p. 88-94. 
42. Richards, R.I. and G.R. Sutherland, Simple repeat DNA is not replicated simply. Nat Genet, 
1994. 6(2): p. 114-6. 
43. Modrich, P., Mismatch repair, genetic stability, and cancer. Science, 1994. 266(5193): p. 
1959-60. 
44. Cleary, J.D. and C.E. Pearson, The contribution of cis-elements to disease-associated repeat 
instability: clinical and experimental evidence. Cytogenet Genome Res, 2003. 100(1-4): p. 
25-55. 
45. Mangiarini, L., et al., Instability of highly expanded CAG repeats in mice transgenic for the 
Huntington's disease mutation. Nat Genet, 1997. 15(2): p. 197-200. 
46. Tsilfidis, C., et al., Correlation between CTG trinucleotide repeat length and frequency of 
severe congenital myotonic dystrophy. Nat Genet, 1992. 1(3): p. 192-5. 
47. Wells, R.D., et al., Small slipped register genetic instabilities in Escherichia coli in triplet 
repeat sequences associated with hereditary neurological diseases. J Biol Chem, 1998. 
273(31): p. 19532-41. 
48. Richard, G.F., B. Dujon, and J.E. Haber, Double-strand break repair can lead to high 
frequencies of deletions within short CAG/CTG trinucleotide repeats. Mol Gen Genet, 1999. 
261(4-5): p. 871-82. 
49. Kaytor, M.D., et al., Increased trinucleotide repeat instability with advanced maternal age. 
Hum Mol Genet, 1997. 6(12): p. 2135-9. 
50. Wolozin, B. and C. Behl, Mechanisms of neurodegenerative disorders: Part 1: protein 
aggregates. Arch Neurol, 2000. 57(6): p. 793-6. 
51. Myers, R.H., et al., Clinical and neuropathologic assessment of severity in Huntington's 
disease. Neurology, 1988. 38(3): p. 341-7. 
52. Becher, M.W., et al., Intranuclear neuronal inclusions in Huntington's disease and 
dentatorubral and pallidoluysian atrophy: correlation between the density of inclusions and 
IT15 CAG triplet repeat length. Neurobiol Dis, 1998. 4(6): p. 387-97. 
53. Becher, M.W. and C.A. Ross, Intranuclear neuronal inclusions in DRPLA. Mov Disord, 1998. 
13(5): p. 852-3. 
54. Arrasate, M., et al., Inclusion body formation reduces levels of mutant huntingtin and the 
risk of neuronal death. Nature, 2004. 431(7010): p. 805-10. 
Chapter 9. References 
85 
55. Fujigasaki, H., et al., Preferential recruitment of ataxin-3 independent of expanded 
polyglutamine: an immunohistochemical study on Marinesco bodies. J Neurol Neurosurg 
Psychiatry, 2001. 71(4): p. 518-20. 
56. Chai, Y., et al., Evidence for proteasome involvement in polyglutamine disease: localization 
to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro. 
Hum Mol Genet, 1999. 8(4): p. 673-82. 
57. Schmidt, T., et al., Protein surveillance machinery in brains with spinocerebellar ataxia type 
3: redistribution and differential recruitment of 26S proteasome subunits and chaperones to 
neuronal intranuclear inclusions. Ann Neurol, 2002. 51(3): p. 302-10. 
58. Chai, Y., et al., Analysis of the role of heat shock protein (Hsp) molecular chaperones in 
polyglutamine disease. J Neurosci, 1999. 19(23): p. 10338-47. 
59. Paulson, H.L., et al., Intranuclear inclusions of expanded polyglutamine protein in 
spinocerebellar ataxia type 3. Neuron, 1997. 19(2): p. 333-44. 
60. Chai, Y., et al., Poly-ubiquitin binding by the polyglutamine disease protein ataxin-3 links its 
normal function to protein surveillance pathways. J Biol Chem, 2004. 279(5): p. 3605-11. 
61. Kim, S., et al., Polyglutamine protein aggregates are dynamic. Nat Cell Biol, 2002. 4(10): p. 
826-31. 
62. Bence, N.F., R.M. Sampat, and R.R. Kopito, Impairment of the ubiquitin-proteasome system 
by protein aggregation. Science, 2001. 292(5521): p. 1552-5. 
63. Holmberg, C.I., et al., Inefficient degradation of truncated polyglutamine proteins by the 
proteasome. EMBO J, 2004. 23(21): p. 4307-18. 
64. Takahashi, J., et al., Recruitment of nonexpanded polyglutamine proteins to intranuclear 
aggregates in neuronal intranuclear hyaline inclusion disease. J Neuropathol Exp Neurol, 
2001. 60(4): p. 369-76. 
65. Okazawa, H., Polyglutamine diseases: a transcription disorder? Cell Mol Life Sci, 2003. 
60(7): p. 1427-39. 
66. McCampbell, A., et al., CREB-binding protein sequestration by expanded polyglutamine. 
Hum Mol Genet, 2000. 9(14): p. 2197-202. 
67. Taylor, J.P., et al., Aberrant histone acetylation, altered transcription, and retinal 
degeneration in a Drosophila model of polyglutamine disease are rescued by CREB-binding 
protein. Genes Dev, 2003. 17(12): p. 1463-8. 
Chapter 9. References 
86 
68. Li, S.H., et al., Interaction of Huntington disease protein with transcriptional activator Sp1. 
Mol Cell Biol, 2002. 22(5): p. 1277-87. 
69. Li, F., et al., Ataxin-3 is a histone-binding protein with two independent transcriptional 
corepressor activities. J Biol Chem, 2002. 277(47): p. 45004-12. 
70. Dunah, A.W., et al., Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's 
disease. Science, 2002. 296(5576): p. 2238-43. 
71. Hirose, Y. and J.L. Manley, RNA polymerase II and the integration of nuclear events. Genes 
Dev, 2000. 14(12): p. 1415-29. 
72. Grewal, S.I. and D. Moazed, Heterochromatin and epigenetic control of gene expression. 
Science, 2003. 301(5634): p. 798-802. 
73. Steffan, J.S., et al., Histone deacetylase inhibitors arrest polyglutamine-dependent 
neurodegeneration in Drosophila. Nature, 2001. 413(6857): p. 739-43. 
74. Ferrante, R.J., et al., Histone deacetylase inhibition by sodium butyrate chemotherapy 
ameliorates the neurodegenerative phenotype in Huntington's disease mice. J Neurosci, 
2003. 23(28): p. 9418-27. 
75. Hockly, E., et al., Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, 
ameliorates motor deficits in a mouse model of Huntington's disease. Proc Natl Acad Sci U 
S A, 2003. 100(4): p. 2041-6. 
76. Beal, M.F., Energetics in the pathogenesis of neurodegenerative diseases. Trends Neurosci, 
2000. 23(7): p. 298-304. 
77. Orth, M. and A.H. Schapira, Mitochondria and degenerative disorders. Am J Med Genet, 
2001. 106(1): p. 27-36. 
78. Brookes, P.S., et al., Calcium, ATP, and ROS: a mitochondrial love-hate triangle. Am J 
Physiol Cell Physiol, 2004. 287(4): p. C817-33. 
79. Carreras, M.C., et al., Nitric oxide, complex I, and the modulation of mitochondrial reactive 
species in biology and disease. Mol Aspects Med, 2004. 25(1-2): p. 125-39. 
80. Beal, M.F., Mitochondria, free radicals, and neurodegeneration. Curr Opin Neurobiol, 1996. 
6(5): p. 661-6. 
81. Lenaz, G., et al., Mitochondrial bioenergetics in aging. Biochim Biophys Acta, 2000. 1459(2-
3): p. 397-404. 
Chapter 9. References 
87 
82. Zhou, C., Y. Huang, and S. Przedborski, Oxidative stress in Parkinson's disease: a 
mechanism of pathogenic and therapeutic significance. Ann N Y Acad Sci, 2008. 1147: p. 
93-104. 
83. Sas, K., et al., Mitochondria, metabolic disturbances, oxidative stress and the kynurenine 
system, with focus on neurodegenerative disorders. J Neurol Sci, 2007. 257(1-2): p. 221-
39. 
84. Landwehrmeyer, G.B., et al., Huntington's disease gene: regional and cellular expression in 
brain of normal and affected individuals. Ann Neurol, 1995. 37(2): p. 218-30. 
85. Aronin, N., et al., CAG expansion affects the expression of mutant Huntingtin in the 
Huntington's disease brain. Neuron, 1995. 15(5): p. 1193-201. 
86. Ratovitski, T., et al., Mutant huntingtin N-terminal fragments of specific size mediate 
aggregation and toxicity in neuronal cells. J Biol Chem, 2009. 284(16): p. 10855-67. 
87. Havel, L.S., S. Li, and X.J. Li, Nuclear accumulation of polyglutamine disease proteins and 
neuropathology. Mol Brain, 2009. 2(1): p. 21. 
88. Sittler, A., et al., SH3GL3 associates with the Huntingtin exon 1 protein and promotes the 
formation of polygln-containing protein aggregates. Mol Cell, 1998. 2(4): p. 427-36. 
89. Subramaniam, S., et al., Rhes, a striatal specific protein, mediates mutant-huntingtin 
cytotoxicity. Science, 2009. 324(5932): p. 1327-30. 
90. Matilla, A., et al., The cerebellar leucine-rich acidic nuclear protein interacts with ataxin-1. 
Nature, 1997. 389(6654): p. 974-8. 
91. Mattson, M.P., Apoptosis in neurodegenerative disorders. Nat Rev Mol Cell Biol, 2000. 1(2): 
p. 120-9. 
92. Andersen, J.K., Does neuronal loss in Parkinson's disease involve programmed cell death? 
Bioessays, 2001. 23(7): p. 640-6. 
93. Kroemer, G., et al., Classification of cell death: recommendations of the Nomenclature 
Committee on Cell Death. Cell Death Differ, 2005. 12 Suppl 2: p. 1463-7. 
94. Melino, G., R.A. Knight, and P. Nicotera, How many ways to die? How many different 
models of cell death? Cell Death Differ, 2005. 12 Suppl 2: p. 1457-62. 
95. Jacobson, M.D., M. Weil, and M.C. Raff, Programmed cell death in animal development. 
Cell, 1997. 88(3): p. 347-54. 
96. Degterev, A., M. Boyce, and J. Yuan, A decade of caspases. Oncogene, 2003. 22(53): p. 
8543-67. 
Chapter 9. References 
88 
97. Jin, Z. and W.S. El-Deiry, Overview of cell death signaling pathways. Cancer Biol Ther, 2005. 
4(2): p. 139-63. 
98. Reed, J.C., Apoptosis-based therapies. Nat Rev Drug Discov, 2002. 1(2): p. 111-21. 
99. Ranger, A.M., B.A. Malynn, and S.J. Korsmeyer, Mouse models of cell death. Nat Genet, 
2001. 28(2): p. 113-8. 
100. Ron, D. and P. Walter, Signal integration in the endoplasmic reticulum unfolded protein 
response. Nat Rev Mol Cell Biol, 2007. 8(7): p. 519-29. 
101. Malhotra, J.D. and R.J. Kaufman, The endoplasmic reticulum and the unfolded protein 
response. Semin Cell Dev Biol, 2007. 18(6): p. 716-31. 
102. Lindholm, D., H. Wootz, and L. Korhonen, ER stress and neurodegenerative diseases. Cell 
Death Differ, 2006. 13(3): p. 385-92. 
103. Proskuryakov, S.Y., V.L. Gabai, and A.G. Konoplyannikov, Necrosis is an active and 
controlled form of programmed cell death. Biochemistry (Mosc), 2002. 67(4): p. 387-408. 
104. Lockshin, R.A. and Z. Zakeri, Caspase-independent cell death? Oncogene, 2004. 23(16): p. 
2766-73. 
105. Vande Velde, C., et al., BNIP3 and genetic control of necrosis-like cell death through the 
mitochondrial permeability transition pore. Mol Cell Biol, 2000. 20(15): p. 5454-68. 
106. Lenardo, M., et al., Mature T lymphocyte apoptosis--immune regulation in a dynamic and 
unpredictable antigenic environment. Annu Rev Immunol, 1999. 17: p. 221-53. 
107. Levine, B. and D.J. Klionsky, Development by self-digestion: molecular mechanisms and 
biological functions of autophagy. Dev Cell, 2004. 6(4): p. 463-77. 
108. Kelekar, A., Autophagy. Ann N Y Acad Sci, 2005. 1066: p. 259-71. 
109. Pattingre, S. and B. Levine, Bcl-2 inhibition of autophagy: a new route to cancer? Cancer 
Res, 2006. 66(6): p. 2885-8. 
110. Shimizu, S., et al., Role of Bcl-2 family proteins in a non-apoptotic programmed cell death 
dependent on autophagy genes. Nat Cell Biol, 2004. 6(12): p. 1221-8. 
111. Kessel, D., et al., Determinants of the apoptotic response to lysosomal photodamage. 
Photochem Photobiol, 2000. 71(2): p. 196-200. 
112. Qin, Z.H., et al., Autophagy regulates the processing of amino terminal huntingtin fragments. 
Hum Mol Genet, 2003. 12(24): p. 3231-44. 
113. Anglade, P., et al., Apoptosis and autophagy in nigral neurons of patients with Parkinson's 
disease. Histol Histopathol, 1997. 12(1): p. 25-31. 
Chapter 9. References 
89 
114. Yu, W.H., et al., Autophagic vacuoles are enriched in amyloid precursor protein-secretase 
activities: implications for beta-amyloid peptide over-production and localization in 
Alzheimer's disease. Int J Biochem Cell Biol, 2004. 36(12): p. 2531-40. 
115. Nixon, R.A., et al., Extensive involvement of autophagy in Alzheimer disease: an immuno-
electron microscopy study. J Neuropathol Exp Neurol, 2005. 64(2): p. 113-22. 
116. Yu, W.H., et al., Macroautophagy - a novel beta-amyloid peptide-generating pathway 
activated in Alzheimer's disease. Journal of Cell Biology, 2005. 171(1): p. 87-98. 
117. Anglade, P., et al., Apoptosis and autophagy in nigral neurons of patients with Parkinson's 
disease. Histology and Histopathology, 1997. 12(1): p. 25-31. 
118. Cataldo, A.M., et al., Properties of the endosomal-lysosomal system in the human central 
nervous system: Disturbances mark most neurons in populations at risk to degenerate in 
Alzheimer's disease. Journal of Neuroscience, 1996. 16(1): p. 186-199. 
119. Moreira, P.I., et al., Autophagocytosis of mitochondria is prominent in Alzheimer disease (vol 
66, pg 525, 2007). Journal of Neuropathology and Experimental Neurology, 2007. 66(7): p. 
674-674. 
120. Nakano, K.K., D.M. Dawson, and A. Spence, Machado disease. A hereditary ataxia in 
Portuguese emigrants to Massachusetts. Neurology, 1972. 22(1): p. 49-55. 
121. Woods, B.T. and H.H. Schaumburg, Nigro-spino-dentatal degeneration with nuclear 
ophthalmoplegia. A unique and partially treatable clinico-pathological entity. J Neurol Sci, 
1972. 17(2): p. 149-66. 
122. Rosenberg, R.N., W.L. Nyhan, and C. Bay, Autosomal dominant striatonigral degeneration: a 
clinical, pathological, and biochemical study of a new genetic disorder. Trans Am Neurol 
Assoc, 1976. 101: p. 78-80. 
123. Coutinho, P. and C. Andrade, Autosomal dominant system degeneration in Portuguese 
families of the Azores Islands. A new genetic disorder involving cerebellar, pyramidal, 
extrapyramidal and spinal cord motor functions. Neurology, 1978. 28(7): p. 703-9. 
124. Lima, L. and P. Coutinho, Clinical criteria for diagnosis of Machado-Joseph disease: report 
of a non-Azorena Portuguese family. Neurology, 1980. 30(3): p. 319-22. 
125. Sequeiros, J. and P. Coutinho, Epidemiology and clinical aspects of Machado-Joseph 
disease. Adv Neurol, 1993. 61: p. 139-53. 
Chapter 9. References 
90 
126. Rub, U., et al., Guidelines for the pathoanatomical examination of the lower brain stem in 
ingestive and swallowing disorders and its application to a dysphagic spinocerebellar ataxia 
type 3 patient. Neuropathol Appl Neurobiol, 2003. 29(1): p. 1-13. 
127. Rosenberg, R.N., Machado-Joseph disease: an autosomal dominant motor system 
degeneration. Mov Disord, 1992. 7(3): p. 193-203. 
128. Yamada, M., et al., Sharing of polyglutamine localization by the neuronal nucleus and 
cytoplasm in CAG-repeat diseases. Neuropathol Appl Neurobiol, 2004. 30(6): p. 665-75. 
129. Coutinho, P. and J. Sequeiros, [Clinical, genetic and pathological aspects of Machado-
Joseph disease]. J Genet Hum, 1981. 29(3): p. 203-9. 
130. Rub, U., et al., Spinocerebellar ataxia type 3 (SCA3): thalamic neurodegeneration occurs 
independently from thalamic ataxin-3 immunopositive neuronal intranuclear inclusions. 
Brain Pathol, 2006. 16(3): p. 218-27. 
131. Iwabuchi, K., et al., Autosomal dominant spinocerebellar degenerations. Clinical, 
pathological, and genetic correlations. Rev Neurol (Paris), 1999. 155(4): p. 255-70. 
132. Takiyama, Y., et al., The gene for Machado-Joseph disease maps to human chromosome 
14q. Nat Genet, 1993. 4(3): p. 300-4. 
133. Gaspar, C., et al., Ancestral origins of the Machado-Joseph disease mutation: a worldwide 
haplotype study. Am J Hum Genet, 2001. 68(2): p. 523-8. 
134. Ichikawa, Y., et al., The genomic structure and expression of MJD, the Machado-Joseph 
disease gene. J Hum Genet, 2001. 46(7): p. 413-22. 
135. Bettencourt, C., et al., Increased transcript diversity: novel splicing variants of Machado-
Joseph Disease gene (ATXN3). Neurogenetics, 2009. 
136. Nishiyama, K., et al., Regional and cellular expression of the Machado-Joseph disease gene 
in brains of normal and affected individuals. Ann Neurol, 1996. 40(5): p. 776-81. 
137. Goto, J., et al., Machado-Joseph disease gene products carrying different carboxyl termini. 
Neurosci Res, 1997. 28(4): p. 373-7. 
138. Albrecht, M., et al., Structural modeling of ataxin-3 reveals distant homology to adaptins. 
Proteins, 2003. 50(2): p. 355-70. 
139. Hofmann, K. and L. Falquet, A ubiquitin-interacting motif conserved in components of the 
proteasomal and lysosomal protein degradation systems. Trends Biochem Sci, 2001. 26(6): 
p. 347-50. 
Chapter 9. References 
91 
140. Burnett, B., F. Li, and R.N. Pittman, The polyglutamine neurodegenerative protein ataxin-3 
binds polyubiquitylated proteins and has ubiquitin protease activity. Hum Mol Genet, 2003. 
12(23): p. 3195-205. 
141. Rodrigues, A.J., et al., Functional genomics and biochemical characterization of the C. 
elegans orthologue of the Machado-Joseph disease protein ataxin-3. FASEB J, 2007. 21(4): 
p. 1126-36. 
142. Doss-Pepe, E.W., et al., Ataxin-3 interactions with rad23 and valosin-containing protein and 
its associations with ubiquitin chains and the proteasome are consistent with a role in 
ubiquitin-mediated proteolysis. Mol Cell Biol, 2003. 23(18): p. 6469-83. 
143. Dhananjayan, S.C., A. Ismail, and Z. Nawaz, Ubiquitin and control of transcription. Essays 
Biochem, 2005. 41: p. 69-80. 
144. Evert, B.O., et al., Ataxin-3 represses transcription via chromatin binding, interaction with 
histone deacetylase 3, and histone deacetylation. J Neurosci, 2006. 26(44): p. 11474-86. 
145. Gales, L., et al., Towards a structural understanding of the fibrillization pathway in Machado-
Joseph's disease: trapping early oligomers of non-expanded ataxin-3. J Mol Biol, 2005. 
353(3): p. 642-54. 
146. Riess, O., et al., SCA3: neurological features, pathogenesis and animal models. Cerebellum, 
2008. 7(2): p. 125-37. 
147. Taft, R.A., M. Davisson, and M.V. Wiles, Know thy mouse. Trends Genet, 2006. 22(12): p. 
649-53. 
148. Cemal, C.K., et al., YAC transgenic mice carrying pathological alleles of the MJD1 locus 
exhibit a mild and slowly progressive cerebellar deficit. Hum Mol Genet, 2002. 11(9): p. 
1075-94. 
149. Goti, D., et al., A mutant ataxin-3 putative-cleavage fragment in brains of Machado-Joseph 
disease patients and transgenic mice is cytotoxic above a critical concentration. J Neurosci, 
2004. 24(45): p. 10266-79. 
150. Bichelmeier, U., et al., Nuclear localization of ataxin-3 is required for the manifestation of 
symptoms in SCA3: in vivo evidence. J Neurosci, 2007. 27(28): p. 7418-28. 
151. Chou, A.H., et al., Polyglutamine-expanded ataxin-3 causes cerebellar dysfunction of SCA3 
transgenic mice by inducing transcriptional dysregulation. Neurobiol Dis, 2008. 31(1): p. 
89-101. 
Chapter 9. References 
92 
152. Alves, S., et al., Striatal and nigral pathology in a lentiviral rat model of Machado-Joseph 
disease. Hum Mol Genet, 2008. 17(14): p. 2071-83. 
153. Rub, U., E.R. Brunt, and T. Deller, New insights into the pathoanatomy of spinocerebellar 
ataxia type 3 (Machado-Joseph disease). Curr Opin Neurol, 2008. 21(2): p. 111-6. 
154. Eng, L.F., R.S. Ghirnikar, and Y.L. Lee, Glial fibrillary acidic protein: GFAP-thirty-one years 
(1969-2000). Neurochem Res, 2000. 25(9-10): p. 1439-51. 
155. Vohra, B.P., et al., Dark neurons in the ageing cerebellum: their mode of formation and 
effect of Maharishi Amrit Kalash. Biogerontology, 2002. 3(6): p. 347-54. 
156. Durr, A., et al., Spinocerebellar ataxia 3 and Machado-Joseph disease: clinical, molecular, 
and neuropathological features. Ann Neurol, 1996. 39(4): p. 490-9. 
157. Braak, H., [Nuclei of the human brain stem. IV. Nucleus reticularis lateralis and its 
satellites]. Z Zellforsch Mikrosk Anat, 1971. 122(2): p. 145-59. 
158. Braak, H. and E. Braak, Involvement of precerebellar nuclei in Pick's disease. Exp Neurol, 
1998. 153(2): p. 351-65. 
159. Braak, H., U. Rub, and K. Del Tredici, Involvement of precerebellar nuclei in multiple system 
atrophy. Neuropathol Appl Neurobiol, 2003. 29(1): p. 60-76. 
160. Barmack, N.H., Central vestibular system: vestibular nuclei and posterior cerebellum. Brain 
Res Bull, 2003. 60(5-6): p. 511-41. 
161. Rub, U., et al., Spinocerebellar ataxias types 2 and 3: degeneration of the pre-cerebellar 
nuclei isolates the three phylogenetically defined regions of the cerebellum. J Neural 
Transm, 2005. 112(11): p. 1523-45. 
162. Davies, S.W., et al., Formation of neuronal intranuclear inclusions underlies the neurological 
dysfunction in mice transgenic for the HD mutation. Cell, 1997. 90(3): p. 537-48. 
163. Reddy, P.H., et al., Behavioural abnormalities and selective neuronal loss in HD transgenic 
mice expressing mutated full-length HD cDNA. Nat Genet, 1998. 20(2): p. 198-202. 
164. Klement, I.A., et al., Ataxin-1 nuclear localization and aggregation: role in polyglutamine-
induced disease in SCA1 transgenic mice. Cell, 1998. 95(1): p. 41-53. 
165. Kanda, T., et al., Type III Machado-Joseph disease in a Japanese family: a 
clinicopathological study with special reference to the peripheral nervous system. Clin 
Neuropathol, 1989. 8(3): p. 134-41. 
166. Pou-Serradell, A., et al., [Machado-Joseph disease in a family of Spanish origin]. Rev Neurol 
(Paris), 1987. 143(6-7): p. 520-5. 
Chapter 9. References 
93 
167. Yuasa, T., et al., Joseph's disease: clinical and pathological studies in a Japanese family. 
Ann Neurol, 1986. 19(2): p. 152-7. 
168. Pozzi, C., et al., Study of subcellular localization and proteolysis of ataxin-3. Neurobiol Dis, 
2008. 30(2): p. 190-200. 
169. Blank, M. and Y. Shiloh, Programs for cell death: apoptosis is only one way to go. Cell Cycle, 
2007. 6(6): p. 686-95. 
170. Wyllie, A.H., J.F. Kerr, and A.R. Currie, Cell death: the significance of apoptosis. Int Rev 
Cytol, 1980. 68: p. 251-306. 
171. Baines, C.P., et al., Loss of cyclophilin D reveals a critical role for mitochondrial permeability 
transition in cell death. Nature, 2005. 434(7033): p. 658-62. 
172. Nakagawa, T., et al., Cyclophilin D-dependent mitochondrial permeability transition regulates 
some necrotic but not apoptotic cell death. Nature, 2005. 434(7033): p. 652-8. 
173. Jaeger, P.A. and T. Wyss-Coray, All-you-can-eat: autophagy in neurodegeneration and 
neuroprotection. Mol Neurodegener, 2009. 4: p. 16. 
174. Vis, J.C., et al., Expression pattern of apoptosis-related markers in Huntington's disease. 
Acta Neuropathol, 2005. 109(3): p. 321-8. 
175. Portera-Cailliau, C., et al., Evidence for apoptotic cell death in Huntington disease and 
excitotoxic animal models. J Neurosci, 1995. 15(5 Pt 2): p. 3775-87. 
176. Teles, A.V., et al., Increase in bax expression and apoptosis are associated in Huntington's 
disease progression. Neurosci Lett, 2008. 438(1): p. 59-63. 
177. Dong, Z., et al., Internucleosomal DNA cleavage triggered by plasma membrane damage 
during necrotic cell death. Involvement of serine but not cysteine proteases. Am J Pathol, 
1997. 151(5): p. 1205-13. 
178. Fukuda, K., M. Kojiro, and J.F. Chiu, Demonstration of extensive chromatin cleavage in 
transplanted Morris hepatoma 7777 tissue: apoptosis or necrosis? Am J Pathol, 1993. 
142(3): p. 935-46. 
179. Beilharz, E.J., et al., Mechanisms of delayed cell death following hypoxic-ischemic injury in 
the immature rat: evidence for apoptosis during selective neuronal loss. Brain Res Mol Brain 
Res, 1995. 29(1): p. 1-14. 
180. Rink, A., et al., Evidence of apoptotic cell death after experimental traumatic brain injury in 
the rat. Am J Pathol, 1995. 147(6): p. 1575-83. 
181. Fraser, A. and G. Evan, A license to kill. Cell, 1996. 85(6): p. 781-4. 
Chapter 9. References 
94 
182. Yuan, J., et al., The C. elegans cell death gene ced-3 encodes a protein similar to 
mammalian interleukin-1 beta-converting enzyme. Cell, 1993. 75(4): p. 641-52. 
183. Chen, M., et al., Minocycline inhibits caspase-1 and caspase-3 expression and delays 
mortality in a transgenic mouse model of Huntington disease. Nat Med, 2000. 6(7): p. 797-
801. 
184. Kiechle, T., et al., Cytochrome C and caspase-9 expression in Huntington's disease. 
Neuromolecular Med, 2002. 1(3): p. 183-95. 
185. Schmued, L.C. and K.J. Hopkins, Fluoro-Jade B: a high affinity fluorescent marker for the 
localization of neuronal degeneration. Brain Res, 2000. 874(2): p. 123-30. 
186. Clark, H.B., et al., Purkinje cell expression of a mutant allele of SCA1 in transgenic mice 
leads to disparate effects on motor behaviors, followed by a progressive cerebellar 
dysfunction and histological alterations. J Neurosci, 1997. 17(19): p. 7385-95. 
187. Garden, G.A., et al., Polyglutamine-expanded ataxin-7 promotes non-cell-autonomous 
purkinje cell degeneration and displays proteolytic cleavage in ataxic transgenic mice. J 
Neurosci, 2002. 22(12): p. 4897-905. 
188. Sanpei, K., et al., Identification of the spinocerebellar ataxia type 2 gene using a direct 
identification of repeat expansion and cloning technique, DIRECT. Nat Genet, 1996. 14(3): 
p. 277-84. 
189. Sato, T., et al., Severe neurological phenotypes of Q129 DRPLA transgenic mice 
serendipitously created by en masse expansion of CAG repeats in Q76 DRPLA mice. Hum 
Mol Genet, 2009. 18(4): p. 723-36. 
190. Slemmer, J.E., C.I. De Zeeuw, and J.T. Weber, Don't get too excited: mechanisms of 
glutamate-mediated Purkinje cell death. Prog Brain Res, 2005. 148: p. 367-90. 
191. Yu, Y.C., et al., Decreased antioxidant enzyme activity and increased mitochondrial DNA 
damage in cellular models of Machado-Joseph disease. J Neurosci Res, 2009. 87(8): p. 
1884-91. 
192. Tsuji, S., Unstable expansion of triplet repeats as a new disease mechanism for 
neurodegenerative diseases. Jpn J Hum Genet, 1996. 41(3): p. 279-90. 
193. Padiath, Q.S., et al., Identification of a novel 45 repeat unstable allele associated with a 
disease phenotype at the MJD1/SCA3 locus. Am J Med Genet B Neuropsychiatr Genet, 
2005. 133B(1): p. 124-6. 
Chapter 9. References 
95 
194. Takiyama, Y., et al., Evidence for inter-generational instability in the CAG repeat in the MJD1 
gene and for conserved haplotypes at flanking markers amongst Japanese and Caucasian 
subjects with Machado-Joseph disease. Hum Mol Genet, 1995. 4(7): p. 1137-46. 
195. Lang, A.E., et al., Homozygous inheritance of the Machado-Joseph disease gene. Ann 
Neurol, 1994. 36(3): p. 443-7. 
196. Pearson, C.E., K. Nichol Edamura, and J.D. Cleary, Repeat instability: mechanisms of 
dynamic mutations. Nat Rev Genet, 2005. 6(10): p. 729-42. 
197. Vogel, F. and R. Rathenberg, Spontaneous mutation in man. Adv Hum Genet, 1975. 5: p. 
223-318. 
198. Heller, C.H. and Y. Clermont, Kinetics of the Germinal Epithelium in Man. Recent Prog 
Horm Res, 1964. 20: p. 545-75. 
199. Hashida, H., et al., Brain regional differences in the expansion of a CAG repeat in the 
spinocerebellar ataxias: dentatorubral-pallidoluysian atrophy, Machado-Joseph disease, and 
spinocerebellar ataxia type 1. Ann Neurol, 1997. 41(4): p. 505-11. 
200. Anvret, M., et al., Larger expansions of the CTG repeat in muscle compared to lymphocytes 
from patients with myotonic dystrophy. Hum Mol Genet, 1993. 2(9): p. 1397-400. 
201. Thornton, C.A., K. Johnson, and R.T. Moxley, 3rd, Myotonic dystrophy patients have larger 
CTG expansions in skeletal muscle than in leukocytes. Ann Neurol, 1994. 35(1): p. 104-7. 
202. Kennedy, L. and P.F. Shelbourne, Dramatic mutation instability in HD mouse striatum: does 
polyglutamine load contribute to cell-specific vulnerability in Huntington's disease? Hum Mol 
Genet, 2000. 9(17): p. 2539-44. 
203. Huang, J. and D. Moazed, Association of the RENT complex with nontranscribed and coding 
regions of rDNA and a regional requirement for the replication fork block protein Fob1 in 
rDNA silencing. Genes Dev, 2003. 17(17): p. 2162-76. 
204. Maciel, P., et al., Improvement in the molecular diagnosis of Machado-Joseph disease. Arch 
Neurol, 2001. 58(11): p. 1821-7. 
205. Cancel, G., et al., Somatic mosaicism of the CAG repeat expansion in spinocerebellar ataxia 
type 3/Machado-Joseph disease. Hum Mutat, 1998. 11(1): p. 23-7. 
206. Williams, L.C., et al., Comparative semi-automated analysis of (CAG) repeats in the 
Huntington disease gene: use of internal standards. Mol Cell Probes, 1999. 13(4): p. 283-9. 
Chapter 9. References 
96 
207. Dragileva, E., et al., Intergenerational and striatal CAG repeat instability in Huntington's 
disease knock-in mice involve different DNA repair genes. Neurobiol Dis, 2009. 33(1): p. 37-
47. 
208. Duncan, A.W., C. Dorrell, and M. Grompe, Stem Cells and Liver Regeneration. 
Gastroenterology, 2009. 
209. Lopes-Cendes, I., et al., Somatic mosaicism in the central nervous system in spinocerebellar 
ataxia type 1 and Machado-Joseph disease. Ann Neurol, 1996. 40(2): p. 199-206. 
210. Takano, H., et al., Somatic mosaicism of expanded CAG repeats in brains of patients with 
dentatorubral-pallidoluysian atrophy: cellular population-dependent dynamics of mitotic 
instability. Am J Hum Genet, 1996. 58(6): p. 1212-22. 
211. Tanaka, F., Y. Ito, and G. Sobue, [Somatic mosaicism of expanded CAG trinucleotide repeat 
in the neural and nonneural tissues of Machado-Joseph disease (MJD)]. Nippon Rinsho, 
1999. 57(4): p. 838-42. 
212. Seznec, H., et al., Transgenic mice carrying large human genomic sequences with expanded 
CTG repeat mimic closely the DM CTG repeat intergenerational and somatic instability. Hum 
Mol Genet, 2000. 9(8): p. 1185-94. 
213. Watase, K., et al., Regional differences of somatic CAG repeat instability do not account for 
selective neuronal vulnerability in a knock-in mouse model of SCA1. Hum Mol Genet, 2003. 
12(21): p. 2789-95. 
214. Clark, R.M., et al., The GAA triplet-repeat is unstable in the context of the human FXN locus 
and displays age-dependent expansions in cerebellum and DRG in a transgenic mouse 
model. Hum Genet, 2007. 120(5): p. 633-40. 
215. Ishiguro, H., et al., Age-dependent and tissue-specific CAG repeat instability occurs in mouse 
knock-in for a mutant Huntington's disease gene. J Neurosci Res, 2001. 65(4): p. 289-97. 
216. Sato, T., et al., Transgenic mice harboring a full-length human mutant DRPLA gene exhibit 
age-dependent intergenerational and somatic instabilities of CAG repeats comparable with 
those in DRPLA patients. Hum Mol Genet, 1999. 8(1): p. 99-106. 
217. Winklhofer, K.F., J. Tatzelt, and C. Haass, The two faces of protein misfolding: gain- and 
loss-of-function in neurodegenerative diseases. EMBO J, 2008. 27(2): p. 336-49. 
218. Ravikumar, B., R. Duden, and D.C. Rubinsztein, Aggregate-prone proteins with 
polyglutamine and polyalanine expansions are degraded by autophagy. Hum Mol Genet, 
2002. 11(9): p. 1107-17. 
Chapter 9. References 
97 
219. Ravikumar, B., et al., Inhibition of mTOR induces autophagy and reduces toxicity of 
polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet, 2004. 
36(6): p. 585-95. 
220. Leeflang, E.P., et al., Single sperm analysis of the trinucleotide repeats in the Huntington's 
disease gene: quantification of the mutation frequency spectrum. Hum Mol Genet, 1995. 
4(9): p. 1519-26. 
221. Kennedy, L., et al., Dramatic tissue-specific mutation length increases are an early 
molecular event in Huntington disease pathogenesis. Hum Mol Genet, 2003. 12(24): p. 
3359-67. 
222. Zhang, L., et al., Studying human mutations by sperm typing: instability of CAG trinucleotide 
repeats in the human androgen receptor gene. Nat Genet, 1994. 7(4): p. 531-5. 
